Extracellular matrix compositions
ECM compositions derived from placental tissue, with precise protein and glycosaminoglycan content, address the need for high-purity ECMs by providing sterile, cell-free materials with enhanced water absorption and reduced inflammatory response for diverse medical and cosmetic applications.
Patent Information
- Application Number
- JP2024114592
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2014-08-25
- Filing Date
- 2024-07-18
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a need for improved extracellular matrix (ECM) compositions and methods of manufacturing them, particularly those derived from placental tissue, that are free of contaminants and have specific protein and glycosaminoglycan content suitable for therapeutic and medical applications.
The ECM compositions are prepared from placental tissue, specifically human placental tissue, with controlled amounts of collagen, elastin, fibronectin, laminin, and glycosaminoglycans, and are free of cellular debris, cytokines, and residual reagents, ensuring high purity and sterility.
The ECM compositions exhibit excellent water absorption properties and are suitable for various therapeutic and medical uses, including wound treatment, tissue engineering, and cosmetic applications, with minimal inflammatory response and improved tissue integration.
Smart Images

Figure 2024161378000005 
Figure 2024161378000006 
Figure 2024161378000007
Abstract
Description
[Technical field]
[0001] This application is based on U.S. Patent Application No. 62 / 041468, filed August 25, 2014. The benefit of priority to this application is claimed based on US Pat. is included in the book.
[0002] 1.Technical Field As used herein, the term extracellular matrix (ECM) composition and ECM composition Methods of making the products are also disclosed. Disclosed herein. [Background technology]
[0003] 2. Background technology The extracellular matrix (ECM) forms the sheets that support tendons, ligaments, skin, and internal organs. The proteins that form various structures in the body, including the cellular and metabolic pathways, are still being developed in the art. There is a need for improved ECM compositions and methods of making such ECM compositions. Summary of the Invention [Means for solving the problem]
[0004] 3. Overview In one embodiment, the present disclosure provides a method for the preparation of placental tissue, e.g., human placental tissue. A composition of extracellular matrix (ECM) prepared using tissue.
[0005] In some embodiments, the ECM compositions disclosed herein comprise about 30% It contains about 60% collagen and about 10% to 35% elastin. Such ECM compositions include (i) extremely high levels of cytotoxicity, as measured, for example, by enzyme-linked immunosorbent assay (ELISA); (ii) low levels of fibronectin (e.g., less than 0.1% fibronectin), e.g. Undetectable or undetectable amounts of laminin, and / or For example, undetectable or undetectable amounts of glycosaminoglycans measured by ELISA. include.
[0006] In some embodiments, the ECM compositions disclosed herein comprise about 30% It contains about 72% collagen and about 10% to 35% elastin. Such ECM compositions contain (i) extremely low amounts of fibrinogen, as measured, for example, by ELISA. (ii) fibronectin (e.g., less than 0.1% fibronectin), e.g., by ELISA Laminin measured by, for example, ELISA (less than 0.1% laminin) glycosaminoglycans measured at 0.1% or less (e.g., less than 0.1% glycosaminoglycans); (iii) undetectable or undetectable amounts of cytokines; (iv) undetectable or undetectable amounts of cytokines; (v) undetectable or undetectable amounts of deoxycholic acid; and / or (v) undetectable or undetectable amounts of growth factors. It may contain carboxylic acids.
[0007] The ECM compositions disclosed herein have properties suitable for therapeutic / medical use. In particular, the ECM compositions disclosed herein are sterile and acellular. (e.g., ≧99% cell-free) and / or free of cell debris (fr ee of cellular debris (e.g., ≧99% free of cellular debris). In certain embodiments, the ECM compositions disclosed herein contain cytokines. They contain no or undetectable amounts of cytokines, for example as measured by ELISA. In some embodiments, the ECM compositions further disclosed herein contain no reagent residues. That is, the final ECM composition is devoid of any residual material used in the preparation of the composition. Further, in certain embodiments, the present invention includes a method for the preparation of a method for the preparation of a medicament for use in a pharmaceutical composition comprising the steps of: The ECM compositions shown contain very small amounts of nucleic acid (e.g., ~41-171 ng / mg of dry matter). and endotoxin (e.g., <0.25 EU).
[0008] Another advantageous property of the ECM compositions disclosed herein is their water absorbency. In some embodiments, the ECM compositions disclosed herein contain up to 150% of their own weight. Such properties are, for example, those disclosed herein. The application of the ECM composition to wound treatment is advantageous.
[0009] Certain embodiments disclosed herein contain about 35-55% collagen and about 1 In certain embodiments, the composition comprises an ECM composition comprising 0-30% elastin. The substance contains about 34-53% collagen and about 13-29% elastin. In embodiments, the ECM composition is obtained from placental tissue, e.g., human placental tissue. In other specific embodiments, the ECM composition is, for example, human placenta. In certain other embodiments, the chorion is obtained from the placenta, such as from the chorion of the placenta. The ECM composition contains very little fibronectin, e.g., less than 0.1% fibronectin. fibronectin, less than 0.01% fibronectin or less than 0.001% fibronectin In other specific embodiments, the ECM composition does not contain laminin or In another specific embodiment, the ECM composition comprises an undetectable amount of laminin. Contains no glycosaminoglycans or undetectable amounts of glycosaminoglycans. In certain embodiments, the ECM composition contains very little fibronectin. , e.g., less than 0.1% fibronectin, less than 0.01% fibronectin, or 0 Contains less than .001% fibronectin and contains no or undetectable amounts of laminin. It contains no glycosaminoglycans or undetectable amounts of glycosaminoglycans. Includes cans.
[0010] Certain embodiments disclosed herein contain about 35-72% collagen and about 1 The ECM composition contains 5-25% elastin. Certain embodiments include an E collagen composition that contains about 40-70% collagen and about 15-25% elastin. In another specific embodiment, the composition is a collagen composition comprising 40-70% collagen. In another particular embodiment, the composition comprises 15-22% elastin and 15-22% glycerin. , 43-68% collagen and 18-21% elastin. In the present invention, the ECM composition contains fibronectin, e.g., less than 0.1% fibronectin. fibronectin, less than 0.05% fibronectin, less than 0.01% fibronectin, <0.001% fibronectin, 0.001 to 0.1% fibronectin, 0 .001 to 0.05% fibronectin, 0.001 to 0.01% fibronectin 0.01 to 0.1% fibronectin, or 0.01 to 0.05% In another specific embodiment, the ECM composition comprises laminin, For example, less than 0.1% laminin, less than 0.05% laminin, less than 0.01% laminin Laminin, less than 0.001% Laminin, 0.001 to 0.1% Laminin, 0.001 to 0.05% laminin, 0.001 to 0.01% laminin, 0.01 to 0.1% laminin, or 0.01 to 0.05% laminin. The ECM composition may include glycosaminoglycans, e.g., less than 0.1% glycosaminoglycans. Glycosaminoglycans, less than 0.05% glycosaminoglycans, less than 0.01% glycosaminoglycans Glycans, less than 0.001% glycosaminoglycans, 0.001 to 0.1% glycosaminoglycans Glycosaminoglycans, 0.001 to 0.05% Glycosaminoglycans, 0.001 to 0 .01% glycosaminoglycans, 0.01 to 0.1% glycosaminoglycans, or In another particular embodiment, the composition comprises 0.01 to 0.05% glycosaminoglycan. The ECM composition does not include cytokines, growth factors, and / or deoxycholic acid. or undetectable amounts of cytokines, growth factors and / or deoxycholic acid. In some embodiments, the ECM composition includes fibronectin, e.g., 0.1 % Fibronectin, 0.05% Fibronectin, 0.01% Fibronectin Fibronectin, less than 0.001% fibronectin, 0.001 to 0.1% fibrinogen Lonectin, 0.001 to 0.05% Fibronectin, 0.001 to 0.01% of fibronectin, 0.01 to 0.1% fibronectin, or 0.01 to 0. 0.05% fibronectin and laminin, e.g., less than 0.1% laminin; Less than 0.05% laminin, less than 0.01% laminin, less than 0.001% laminin, 0.001 to 0.1% laminin, 0.001 to 0.05% laminin, 0.001 to 0.01% laminin, 0.01 to 0.1% laminin, or 0.01 to 0.0 Contains 5% laminin and contains glycosaminoglycans, e.g., less than 0.1% glycosaminoglycans. Glycosaminoglycans, less than 0.05% glycosaminoglycans, less than 0.01% glycosaminoglycans Glycans, less than 0.001% glycosaminoglycans, 0.001 to 0.1% glycosaminoglycans Glycosaminoglycans, 0.001 to 0.05% Glycosaminoglycans, 0.001 to 0 .01% glycosaminoglycans, 0.01 to 0.1% glycosaminoglycans, or Contains 0.01 to 0.05% glycosaminoglycans, plus cytokines, growth factors, and Contains no or undetectable amounts of cytokines, growth factors, and / or deoxycholic acid and / or deoxycholic acid. In certain other embodiments, the antibody is obtained from placental tissue, e.g., human placental tissue. The ECM composition is obtained from the placental chorion, e.g., the chorionic plate of the placenta. For example, the chorionic plate derived from the human placenta.
[0011] Other specific embodiments disclosed herein include a collagen composition comprising about 50-60% collagen and The ECM composition comprises about 10-20% elastin. The ECM composition is obtained from placental tissue, for example, human placental tissue. In the present invention, the ECM composition is obtained from placental chorion, for example, chorion from a human placenta. In other specific embodiments, the ECM composition contains very little fibronectin. For example, less than 0.1% fibronectin, less than 0.01% fibronectin In certain other embodiments, the composition comprises less than 0.001% fibronectin. The ECM composition contains no laminin or an undetectable amount of laminin. In an embodiment, the ECM composition is free of or has undetectable glycosaminoglycans. In certain other embodiments, the ECM composition comprises a glycosaminoglycan in an amount sufficient to contains very little fibronectin, e.g., less than 0.1% fibronectin, Contains less than 0.01% fibronectin or less than 0.001% fibronectin, Contains no laminin or undetectable amounts of laminin and no glycosaminoglycans Contains little or no detectable amounts of glycosaminoglycans.
[0012] Other specific embodiments disclosed herein include a collagen composition comprising about 45-55% collagen and In certain embodiments, the ECM composition comprises about 15-25% elastin. The ECM composition is obtained from placental tissue, for example, human placental tissue. In the present invention, the ECM composition is obtained from placental chorion, for example, chorion from a human placenta. In other specific embodiments, the ECM composition contains very little fibronectin. For example, less than 0.1% fibronectin, less than 0.01% fibronectin In certain other embodiments, the composition comprises less than 0.001% fibronectin. The ECM composition contains no laminin or an undetectable amount of laminin. In an embodiment, the ECM composition is free of or has undetectable glycosaminoglycans. In certain other embodiments, the ECM composition comprises a glycosaminoglycan in an amount sufficient to contains very little fibronectin, e.g., less than 0.1% fibronectin, Contains less than 0.01% fibronectin or less than 0.001% fibronectin, Contains no laminin or undetectable amounts of laminin and no glycosaminoglycans Contains little or no detectable amounts of glycosaminoglycans.
[0013] Other specific embodiments disclosed herein include a collagen composition comprising about 40-50% collagen and In certain embodiments, the ECM composition comprises about 20-30% elastin. The ECM composition is obtained from placental tissue, for example, human placental tissue. In the present invention, the ECM composition is obtained from placental chorion, for example, chorion from a human placenta. In other specific embodiments, the ECM composition contains very little fibronectin. For example, less than 0.1% fibronectin, less than 0.01% fibronectin In certain other embodiments, the composition comprises less than 0.001% fibronectin. The ECM composition contains no laminin or an undetectable amount of laminin. In an embodiment, the ECM composition is free of or has undetectable glycosaminoglycans. In certain other embodiments, the ECM composition comprises a glycosaminoglycan in an amount sufficient to contains very little fibronectin, e.g., less than 0.1% fibronectin, Contains less than 0.01% fibronectin or less than 0.001% fibronectin, Contains no laminin or undetectable amounts of laminin and no glycosaminoglycans Contains little or no detectable amounts of glycosaminoglycans.
[0014] Other specific embodiments disclosed herein include a collagen composition comprising about 30-40% collagen and In certain embodiments, the ECM composition comprises about 25-35% elastin. The ECM composition is obtained from placental tissue, for example, human placental tissue. In the present invention, the ECM composition is obtained from placental chorion, for example, chorion from a human placenta. In other specific embodiments, the ECM composition contains very little fibronectin. For example, less than 0.1% fibronectin, less than 0.01% fibronectin In certain other embodiments, the composition comprises less than 0.001% fibronectin. The ECM composition contains no laminin or an undetectable amount of laminin. In an embodiment, the ECM composition is free of or has undetectable glycosaminoglycans. In certain other embodiments, the ECM composition comprises a glycosaminoglycan in an amount sufficient to contains very little fibronectin, e.g., less than 0.1% fibronectin, Contains less than 0.01% fibronectin or less than 0.001% fibronectin, Contains no laminin or undetectable amounts of laminin and no glycosaminoglycans Contains little or no detectable amounts of glycosaminoglycans.
[0015] Other specific embodiments disclosed herein include a collagen composition comprising about 34-43% collagen and In certain embodiments, the ECM composition comprises about 16-24% elastin. The ECM composition is obtained from placental tissue, for example, human placental tissue. In the present invention, the ECM composition is obtained from placental chorion, for example, chorion from a human placenta. In other specific embodiments, the ECM composition contains very little fibronectin. For example, less than 0.1% fibronectin, less than 0.01% fibronectin In certain other embodiments, the composition comprises less than 0.001% fibronectin. The ECM composition contains no laminin or an undetectable amount of laminin. In an embodiment, the ECM composition is free of or has undetectable glycosaminoglycans. In certain other embodiments, the ECM composition comprises a glycosaminoglycan in an amount sufficient to contains very little fibronectin, e.g., less than 0.1% fibronectin, Contains less than 0.01% fibronectin or less than 0.001% fibronectin, Contains no laminin or undetectable amounts of laminin and no glycosaminoglycans Contains little or no detectable amounts of glycosaminoglycans.
[0016] Other specific embodiments disclosed herein include a collagen composition comprising about 37-42% collagen and In certain embodiments, the ECM composition comprises about 16-24% elastin. The ECM composition is obtained from placental tissue, for example, human placental tissue. In the present invention, the ECM composition is obtained from placental chorion, for example, chorion from a human placenta. In other specific embodiments, the ECM composition contains very little fibronectin. For example, less than 0.1% fibronectin, less than 0.01% fibronectin In certain other embodiments, the composition comprises less than 0.001% fibronectin. The ECM composition contains no laminin or an undetectable amount of laminin. In an embodiment, the ECM composition is free of or has undetectable glycosaminoglycans. In certain other embodiments, the ECM composition comprises a glycosaminoglycan in an amount sufficient to contains very little fibronectin, e.g., less than 0.1% fibronectin, Contains less than 0.01% fibronectin or less than 0.001% fibronectin, Contains no laminin or undetectable amounts of laminin and no glycosaminoglycans Contains little or no detectable amounts of glycosaminoglycans.
[0017] Other specific embodiments disclosed herein include about 30-70%, 30-60%, 30-50%, 30-40%, 30-35%, 34-43%, 35-72%, 35-40 %, 37-42%, 40-70%, 40-60%, 40-50%, 40-45%, 40- 65%, 43-68%, 45-50%, 50-55%, or 55-60% collagen and and approximately 10-30%, 10-20%, 10-15%, 15-25%, 15-22%, 15- 20%, 16-24%, 17-24%, 18-21%, 18-20%, 20-24%, 2 ECM containing 0-30%, 20-25%, 25-30%, or 30-35% elastin In certain embodiments, the ECM composition is a composition comprising placental tissue, e.g., human In another specific embodiment, the ECM composition is obtained from placental tissue. The chorion may be obtained from, for example, the chorionic plate of the placenta. The chorion may be, for example, the chorionic plate from the human placenta. In certain other embodiments, the ECM composition comprises a very small amount of fibroblasts. Fibronectin, e.g., less than 0.1% fibronectin, less than 0.05% fibronectin, nectin, less than 0.01% fibronectin, less than 0.001% fibronectin In some embodiments, the ECM composition comprises 0.001 to 0.1% fumarate. Fibronectin, 0.001 to 0.05% Fibronectin, 0.001 to 0.0 1% fibronectin, 0.01 to 0.1% fibronectin, or 0.01 to In certain other embodiments, the ECM composition comprises 0.05% fibronectin. In certain other embodiments, the laminin-containing IgG antibody is free of laminin or contains an undetectable amount of laminin. In this case, the ECM composition contains very little laminin, e.g., less than 0.1% laminin. less than 0.05% laminin, less than 0.01% laminin, or less than 0.001% In certain other embodiments, the ECM composition comprises laminin, e.g. For example, 0.001 to 0.1% laminin, 0.001 to 0.05% laminin, 0. 001 to 0.01% laminin, 0.01 to 0.1% laminin, or 0.01 to In another specific embodiment, the ECM composition comprises 0.05% laminin. Contains no glycosaminoglycans or undetectable amounts of glycosaminoglycans. In certain embodiments, the ECM composition contains minimal amounts of glycosaminoglycans. , e.g., less than 0.1% glycosaminoglycans, less than 0.05% glycosaminoglycans Glycosaminoglycans, less than 0.01% Glycosaminoglycans, less than 0.001% In other specific embodiments, the ECM composition comprises glycosaminoglycans. , e.g., 0.001 to 0.1% glycosaminoglycans, 0.001 to 0.05% glycosaminoglycans, 0.001 to 0.01% glycosaminoglycans, 0.01 to 0.1% glycosaminoglycan, or 0.01 to 0.05% glycosaminoglycan In certain other embodiments, the ECM composition comprises a minimal amount of fibronectin. Fibronectin, e.g., less than 0.1% fibronectin, less than 0.01% fibronectin, Nectin, or less than 0.001% fibronectin, and no laminin or Contains undetectable amounts of laminin and contains no or undetectable amounts of glycosaminoglycans In some embodiments, the ECM composition comprises a fibrinogen. For example, less than 0.1% fibronectin, less than 0.05% fibrinogen Fibronectin, less than 0.01% Fibronectin, less than 0.001% Fibronectin , 0.001 to 0.1% fibronectin, 0.001 to 0.05% fibronectin 0.001 to 0.01% fibronectin, 0.01 to 0.1% fibrin fibronectin, or 0.01 to 0.05% fibronectin, and laminin; For example, less than 0.1% laminin, less than 0.05% laminin, less than 0.01% laminin Laminin, less than 0.001% Laminin, 0.001 to 0.1% Laminin, 0.001 to 0.05% laminin, 0.001 to 0.01% laminin, 0.01 to 0.1% Laminin or 0.01 to 0.05% laminin and glycosaminoglycan , e.g., less than 0.1% glycosaminoglycans, less than 0.05% glycosaminoglycans Glycosaminoglycans, less than 0.01% Glycosaminoglycans, less than 0.001% , 0.001 to 0.1% glycosaminoglycans, 0.001 to 0.05% glycosaminoglycans Glycosaminoglycans, 0.001 to 0.01% Glycosaminoglycans, 0.01 to 0. Contains 1% glycosaminoglycans or 0.01 to 0.05% glycosaminoglycans In addition, the composition contains no or detectable cytokines, growth factors and / or deoxycholic acid. The antibody contains ineffective amounts of cytokines, growth factors and / or deoxycholic acid.
[0018] Other specific embodiments disclosed herein include about 30%, about 35%, about 40%, About 45%, about 50%, about 55%, about 60%, about 65%, about 70% or about 72% collagen and about 10%, about 15%, about 18%, about 20%, about 25%, about 30% or about 35% In a specific embodiment, the ECM composition comprises: In certain other embodiments, the E. coli is obtained from placental tissue, e.g., human placental tissue. The CM composition is obtained from the chorion of the placenta, e.g., the chorionic plate of the placenta. For example, the chorionic plate from human placenta. In another specific embodiment, the ECM composition is , containing very small amounts of fibronectin, e.g., less than 0.1% fibronectin, 0 Less than .05% Fibronectin, Less than 0.01% Fibronectin, Less than 0.001% In some embodiments, the ECM composition comprises 0. 001 to 0.1% fibronectin, 0.001 to 0.05% fibronectin , 0.001 to 0.01% fibronectin, 0.01 to 0.1% fibronectin In certain other embodiments, the antibody comprises 0.01 to 0.05% fibronectin. In this case, the ECM composition contains no laminin or an undetectable amount of laminin. In certain other embodiments, the ECM composition contains very little laminin, e.g. For example, less than 0.1% laminin, less than 0.05% laminin, less than 0.01% laminin, or less than 0.001% laminin. The product contains laminin, e.g., 0.001 to 0.1% laminin, 0.001 to 0. 05% laminin, 0.001 to 0.01% laminin, 0.01 to 0.1% laminin In certain other embodiments, the antibody comprises 0.01 to 0.05% laminin. The ECM composition contains no glycosaminoglycans or contains undetectable amounts of glycosaminoglycans. In certain other embodiments, the ECM composition contains very little glycan. Containing glycosaminoglycans, e.g., less than 0.1% glycosaminoglycans, less than 0.05% Glycosaminoglycans: Less than 0.01% Glycosaminoglycans: Less than 0.001% In another specific embodiment, the ECM composition comprises glycosaminoglycans. Glycosaminoglycans, e.g., 0.001 to 0.1% glycosaminoglycans, 0 .001 to 0.05% glycosaminoglycans, 0.001 to 0.01% glycosaminoglycans glycosaminoglycan, 0.01 to 0.1% glycosaminoglycan, or 0.01 to 0.0 In another specific embodiment, the ECM composition comprises 5% glycosaminoglycans. , containing very small amounts of fibronectin, e.g., less than 0.1% fibronectin, 0 Contains less than 0.01% fibronectin, or less than 0.001% fibronectin, Contains no laminin or undetectable amounts of laminin and no glycosaminoglycans In some embodiments, the glycosaminoglycans are in a low or undetectable amount. The ECM composition includes fibronectin, e.g., less than 0.1% fibronectin, Fibronectin <0.05%, Fibronectin <0.01%, 0.001% Fibronectin, 0.001 to 0.1% Fibronectin, 0.001 to 0.05% fibronectin, 0.001 to 0.01% fibronectin, 0.0 1 to 0.1% fibronectin, or 0.01 to 0.05% fibronectin containing laminin, e.g., less than 0.1% laminin, less than 0.05% laminin, Less than 0.01% laminin, less than 0.001% laminin, 0.001 to 0.1% laminin laminin, 0.001 to 0.05% laminin, 0.001 to 0.01% laminin, Contains 0.01 to 0.1% laminin, or 0.01 to 0.05% laminin, and Containing glycosaminoglycans, e.g., less than 0.1% glycosaminoglycans, less than 0.05% Glycosaminoglycans: Less than 0.01% Glycosaminoglycans: Less than 0.001% glycosaminoglycans, 0.001 to 0.1% glycosaminoglycans, 0.001 to 0.05% glycosaminoglycans, 0.001 to 0.01% glycosaminoglycans cans, 0.01 to 0.1% glycosaminoglycans, or 0.01 to 0.05% Glycosaminoglycans, in addition to cytokines, growth factors and / or deoxycholate Acid-free or undetectable amounts of cytokines, growth factors and / or deoxycholic acid Includes.
[0019] Other specific embodiments disclosed herein include collagen at about 31%, about 32%, , approx. 33%, approx. 34%, approx. 35%, approx. 36%, approx. 37%, approx. 38%, approx. 39%, approx. 40% , 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48% , 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56% ,About 57%,About 58%,About 59%,60%,61%,62%,63%,64%,65%, Contains 66%, 67%, 68%, 69%, 70%, 71%, or 72% elastin and approximately 0%, approx. 11%, approx. 12%, approx. 13%, approx. 14%, approx. 15%, approx. 16%, approx. 17%, approx. 8%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 2 6%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 3 In certain embodiments, the ECM composition comprises 4% or 35%. In certain other embodiments, the method comprises the steps of: obtaining the placental tissue, e.g., human placental tissue; The ECM composition is obtained from the placental chorion, e.g., the chorionic plate of the placenta. For example, the chorionic plate from human placenta. In another specific embodiment, the ECM composition The article contains very little fibronectin, e.g., less than 0.1% fibronectin. , less than 0.05% fibronectin, less than 0.01% fibronectin, 0.001 In some embodiments, the ECM composition comprises less than 5% fibronectin. 0.001 to 0.1% fibronectin, 0.001 to 0.05% fibronectin 0.001 to 0.01% fibronectin, 0.01 to 0.1% fibronectin nectin, or 0.01 to 0.05% fibronectin. The ECM composition does not contain laminin or contains an undetectable amount of laminin. In other specific embodiments, the ECM composition comprises minimal amounts of laminin, For example, less than 0.1% laminin, less than 0.05% laminin, less than 0.01% laminin In certain other embodiments, the ECM comprises less than 0.001% laminin. The composition includes laminin, e.g., 0.001 to 0.1% laminin, 0.001 to 0.05% laminin, 0.001 to 0.01% laminin, 0.01 to 0.1% laminin, or 0.01 to 0.05% laminin. The ECM composition is free of glycosaminoglycans or contains undetectable amounts of glycosaminoglycans. In another specific embodiment, the ECM composition comprises a very small amount of aminoglycan. Glycosaminoglycans, e.g., less than 0.1% glycosaminoglycans, 0.05 % glycosaminoglycans, less than 0.01% glycosaminoglycans, less than 0.001% In certain other embodiments, the ECM composition comprises less than about 100% glycosaminoglycans. Glycosaminoglycans, e.g., 0.001 to 0.1% glycosaminoglycans , 0.001 to 0.05% glycosaminoglycans, 0.001 to 0.01% glycol Glycosaminoglycans, 0.01 to 0.1% Glycosaminoglycans, or 0.01 to 0 In certain other embodiments, the ECM composition comprises 0.05% glycosaminoglycans. The article contains very little fibronectin, e.g., less than 0.1% fibronectin. , less than 0.01% fibronectin, or less than 0.001% fibronectin , containing no laminin or undetectable amounts of laminin, and containing glycosaminoglycans In some embodiments, the glycosaminoglycan is free of or contains an undetectable amount of glycosaminoglycans. The ECM composition may contain fibronectin, e.g., less than 0.1% fibronectin. Fibronectin, less than 0.05% Fibronectin, less than 0.01% Fibronectin, 0.00 <1% Fibronectin, 0.001 to 0.1% Fibronectin, 0.001 to 0.05% fibronectin, 0.001 to 0.01% fibronectin, 0 .01 to 0.1% fibronectin, or 0.01 to 0.05% fibronectin Contains laminin, e.g., less than 0.1% laminin, less than 0.05% laminin Laminin, less than 0.01% Laminin, less than 0.001% Laminin, 0.001 to 0.1% laminin, 0.001 to 0.05% laminin, 0.001 to 0.01% laminin 0.01 to 0.1% laminin, or 0.01 to 0.05% laminin, Glycosaminoglycans, e.g., less than 0.1% glycosaminoglycans, 0.05 % glycosaminoglycans, less than 0.01% glycosaminoglycans, less than 0.001% Less than 0.001 to 0.1% glycosaminoglycans, 0.0 0.01 to 0.05% glycosaminoglycans, 0.001 to 0.01% glycosaminoglycans Glycans, 0.01 to 0.1% glycosaminoglycans, or 0.01 to 0.05% In addition, the glycosaminoglycans may be Contains no or undetectable amounts of cytokines, growth factors and / or deoxycholic acid. Contains cyclic acid.
[0020] The ECM compositions disclosed herein can be prepared by a variety of methods. The type of article can be selected, for example, based on the intended use of the ECM composition. Specific examples of preparations of the ECM compositions disclosed therein are detailed in Section 4.1.1. In certain embodiments, the ECM compositions disclosed herein serve as flowable matrices. For example, the ECM composition is prepared in a form that can be administered using a syringe. In other specific embodiments, the ECM compositions disclosed herein are provided as particles. For example, the ECM composition is prepared in the form of a powder. In some embodiments, the ECM compositions disclosed herein are prepared as sheets. In some embodiments, the ECM compositions disclosed herein are not ECM compositions. It is prepared containing one or more components. See Section 4.1.1.1.
[0021] In some embodiments, the present disclosure provides and laminates comprising at least one ECM sheet. In one embodiment, disclosed herein is a laminate comprising two ECM sheets. In certain embodiments, what is disclosed herein comprises at least one and at least one other planar decellularized tissue (e.g. , decellularized / dehydrated amniotic membrane, or fully decellularized or with a fibroblast layer retained or alternatively, a laminate having a planar artificial tissue. In some embodiments, the laminate comprises multiple ECM sheets, or one or more The ECM sheet and other planar decellularized tissues may be attached to the surface of the tissue by, for example, gluing the tissue with glue (e.g. Adhesives such as natural glues (e.g., fibronectin, fibrin, or synthetic glues) In some embodiments, the molecules may be produced by placing them in contact with each other in the presence of In this case, a laminate is two or more ECM sheets together, or one or more ECM sheets and It may be produced by baking and drying one or more planar decellularized tissues together.
[0022] The ECM compositions disclosed herein can be seeded with one or more types of cells and then That is, the cells may be cultured in the ECM compositions described herein. The ECM compositions may be cultured and grown on the ECM compositions described herein. (e.g., added to a flowable matrix composition of ECM). Any type of cell, including both stem cells and non-stem cells, known in the art, may be used. , sufficiently that the ECM compositions disclosed herein can be seeded and / or cultured. It will be understood that there are no limitations on the types of cells that can be seeded onto the ECM compositions disclosed herein. A non-exhaustive list is disclosed in Section 4.1.2.
[0023] In other aspects, disclosed herein is an ECM composition as described herein. See Section 4.2. In some embodiments, the ECM composition A method for making an article from a placenta (e.g., a human placenta) disclosed herein includes the steps of: The process includes, in order: (i) removing the amnion, chorion, and umbilical cord from the placenta (e.g., from the mother immediately after birth); (ii) removing the cytoplasmic endothelial cell membrane from the placenta (either from a derived placenta or from a preserved placenta); and (iii) removing the cytoplasmic endothelial cell membrane from the placenta tissue. Placental tissue was exposed to a solution that caused osmotic disruption of the combined cells. (iii) contacting the placenta with a solution containing a detergent; and (iv) contacting a base. In some embodiments, the ECM composition is contacted with the placenta. A method for producing a placenta using chorion from a placenta (e.g., a human placenta) is as follows: The method includes the steps of: (i) extracting the placenta (e.g., from a placenta obtained from a mother immediately after birth); (ii) obtaining a chorion (from a placenta or preserved placenta); and (iii) attaching cells attached to the chorion. (iii) exposing the chorion to a solution that causes osmotic disruption of the vesicles; and (iv) contacting the chorion with a solution containing a base. In some embodiments, the method of producing an ECM composition from a placenta comprises: For example, a method using the chorion of the human placenta includes the following steps in order: (i) extracting the fetus from the chorion; From the placenta (e.g., from a placenta obtained from a mother immediately after birth or from a preserved placenta) (ii) obtaining the membrane; (iii) scraping and cleaning the chorion; iii) exposing the chorion to a solution that causes osmotic disruption of the cells bound to the chorion; (iv) contacting the chorion with a solution containing a detergent; and (v) grinding. In some embodiments, the ECM composition is isolated from the placenta and then lyophilized. The method for producing the chorion of a placenta (e.g., a human placenta) includes the following steps: The present invention includes, in order: (i) from the placenta (e.g., from a placenta obtained from a mother immediately after birth; or (ii) obtaining the chorion from the preserved placenta; and (iii) scrubbing and cleaning the chorion. and (iii) exposing the chorion to a solution that causes osmotic disruption of the cells associated with the chorion. (iv) exposing the substrate to a solution containing the first cleaning solution and then to a solution containing the second cleaning solution. contacting the chorion with a solution, the solution comprising a detergent and a phosphate buffer such as EDTA; and (v) lyophilizing. Methods for making the M compositions include combining ingredients such as bases, detergents, chelating agents, etc., as disclosed herein. The composition is used in an amount that results in the production of an ECM composition having the specified characteristics.
[0024] Methods for making the ECM compositions disclosed herein include mixing ingredients such as bases, detergents, etc. Used in an amount that results in the production of an ECM composition having the specific characteristics disclosed herein. .
[0025] In certain embodiments disclosed herein, the method of making an ECM composition includes: (i) administering to a sheep Membranes, chorion, and umbilical cord from the placenta (e.g., from a placenta obtained from a mother immediately after birth, or (ii) removing the remaining placental tissue from the preserved placenta; and (iii) removing the remaining placental tissue from the preserved placenta using, for example, sodium chloride. thorium (NaCl, e.g., 1M NaCl) and other such substances attached to the placental tissue. homogenize by placing in a solution that causes osmotic collapse of the ) (homogenizing) step, and (iii) a homogenizing step, for example with sodium deoxycholate (e.g. A procedure in which the placenta tissue is exposed to a solution containing a detergent such as 2% sodium deoxycholate. (iv) washing the placental tissue with, for example, water; and (v) removing the tissue with, for example, sodium hydroxide. The placental tissue is contacted with a solution containing a base such as sodium hydroxide (e.g., 1M NaOH). (vi) applying an acidic solution, e.g., hydrochloric acid (HCl), to the solution containing the placental tissue. In addition, a step of bringing the pH to neutral or close to neutral (e.g., pH 6.0-8.0) is provided. (vii) separating the placental tissue from the liquid portion of the solution (e.g., by centrifugation); and recovering the placental tissue, thereby producing an ECM composition. The ECM composition produced by the method is usually in a paste form (ECM paste) and is used later. The cells may be frozen and stored after collection for use in the methods described herein or may be frozen and stored after collection for use in the methods described herein immediately. Formulations of ECM, e.g., preparations of ECM sheets, preparations of ECM particles The present invention may be used in the manufacture of, for example, an ECM fluid matrix.
[0026] In other specific embodiments, disclosed herein is a method of making an ECM composition. The method includes (i) extracting a placenta (e.g., a placenta obtained from a mother immediately after birth) (ii) obtaining chorionic membranes (from a placenta that has been previously stored or transferred to a vein) and (iii) subjecting the chorionic tissue to, e.g., A solution bound to the chorionic tissue, such as sodium chloride (NaCl, e.g., 1M NaCl) The chorionic tissue is homogenized by placing it in a solution that causes osmotic disruption of the cells. and (iii) sodium deoxycholate (e.g., 2% sodium deoxycholate). (iv) contacting the chorionic tissue with a solution containing a detergent, e.g., water; (v) washing the chorionic tissue with, for example, sodium hydroxide (NaOH, e.g. contacting the chorionic tissue with a solution containing a base, such as 1M NaOH; i) An acidic solution, e.g., hydrochloric acid (HCl), is added to the solution containing the chorionic tissue to a neutral pH or near neutral pH (e.g., pH 6.0-8.0); and (vii) chorionic The tissue is separated from the liquid portion of the solution (e.g., by centrifugation) and the chorionic tissue is and recovering the ECM composition, thereby producing an ECM composition. The ECM composition is usually in a paste form (ECM paste) and is prepared for later use. After collection, the cells may be frozen and stored, or may be collected and immediately subjected to the ECM preparation described herein. Preparations such as ECM sheet preparations, ECM particle preparations, or ECM flowable matrices. It can be used in manufacturing.
[0027] In other specific embodiments, disclosed herein is a method of making an ECM composition. The method includes (i) removing the chorionic membrane, e.g., the chorionic plate, from the placenta (e.g., immediately after birth). (ii) obtaining a chorionic villus (from a placenta obtained from a mother or from a preserved placenta); (iii) rinsing the chorionic tissue with, for example, sodium chloride (NaCl) Cl, e.g., 0.5M NaCl) (iv) placing the polymer in a solution that induces disintegration, e.g., deoxycholic acid or deoxycholic acid; Sodium deoxycholate (e.g., 2% deoxycholate or sodium deoxycholate The chorionic tissue is contacted with a solution containing a detergent such as ethylhexyl ether, and then rinsed with water, for example (rinsing). (v) a grinding and freeze-drying step; The ECM composition is usually a paste (ECM paste), e.g. For example, the ECM composition may be prepared by pulverization and may be prepared in a variety of shapes or forms. The article may be prepared as an ECM sheet, a preparation of ECM particles, or an ECM flowable matrix, or the like.
[0028] In other specific embodiments, disclosed herein is a method of making an ECM composition. The method includes (i) removing the chorionic membrane, e.g., the chorionic plate, from the placenta (e.g., immediately after birth). (ii) obtaining a chorionic villus (from a placenta obtained from a mother or from a preserved placenta); (iii) rinsing the chorionic tissue with, for example, sodium chloride (NaCl) Cl, e.g., 1.0M NaCl) (iv) placing the polymer in a solution that induces disintegration, e.g., deoxycholic acid or deoxycholic acid; Sodium citrate (e.g., 0.05%-0.2% or 0.3%-0.6% deoxycholic acid) Detergents such as sodium citrate or sodium deoxycholate and EDTA (e.g., 1- The chorionic tissue was then placed in a first detergent solution containing 5 mM EDTA or 5-10 mM EDTA. (v) contacting a soluble glycerol such as deoxycholic acid or sodium deoxycholate (e.g., For example, 0.05%-0.2% or 0.3%-0.6% deoxycholic acid or deoxy Detergents such as sodium cholate) and EDTA (e.g., 1-5 mM EDTA or 5 -10 mM EDTA) and contacting the chorionic tissue with a second detergent solution, e.g. (vi) lyophilizing the decellularized and lyophilized cells; and obtaining a whole chorion, which may be, for example, pulverized to obtain a solution (e.g., The decellularized ECM particles can be prepared by resuspending in a PBS solution (water or phosphate buffered saline). For example, ECM sheets, preparations of ECM particles, or ECM fluids may be formed. The compositions may be prepared in a variety of shapes or forms, such as a solid matrix.
[0029] In certain embodiments, disclosed herein is a method for producing an ECM sheet. The method includes: (i) preparing an ECM paste according to the methods disclosed herein; (ii) suspending the ECM paste, e.g., in water, and placing the ECM in a mold, e.g., and placing the suspended ECM solution on a suitable substrate to form a sheet, such as by placing the ECM solution on a suitable substrate. (iii) freezing the ECM; and (iv) lyophilizing the frozen ECM. (v) removing the freeze-dried ECM from the substrate and immersing it in water; i) drying the ECM, for example using a vacuum dryer.
[0030] In certain embodiments, disclosed herein are methods for producing ECM particles. The method includes: (i) preparing an ECM paste according to the methods disclosed herein; (ii) suspending the ECM paste, for example in water; and (iii) (iv) freezing the ECM; and (v) lyophilizing the frozen ECM. ) grinding the freeze-dried ECM.
[0031] In certain embodiments, the present disclosure provides a method for producing an ECM fluid matrix. A method, comprising: (i) preparing an ECM paste according to the methods disclosed herein; (ii) suspending the ECM paste, for example in water; i) freezing the ECM; and (iv) lyophilizing the frozen ECM. and (v) micronizing the freeze-dried ECM. The M is resuspended in, for example, saline, to generate an ECM fluid matrix.
[0032] In other aspects, disclosed herein are ECM compositions disclosed herein. See Section 4.3. In some embodiments, the methods disclosed herein The ECM compositions are used for therapeutic / medical purposes. See Section 4.3.1. In some embodiments, the ECM compositions disclosed herein are used for cosmetic purposes. Used, see section 4.3.2.
[0033] In certain embodiments, the ECM compositions disclosed herein are useful in the treatment of wounds and / or is used in the management. See Section 4.3.1. The ECM compositions disclosed herein can be used to fill wounds, i.e., as wound fillers. In certain other embodiments, the ECM compositions disclosed herein are used as immunoglobulins. The composition is used to dress (e.g., cover) a wound, such as a burn wound. )) is used.
[0034] In other specific embodiments, the ECM compositions disclosed herein are used to treat, for example, dental defects. Used in the treatment and / or management of dental conditions, including restoring dental prostheses. See Section 4.3.2 I want to be.
[0035] In other specific embodiments, the ECM compositions disclosed herein are used to treat oral lesions. These are used in the treatment and / or management of chronic myocardial infarction and / or cerebrovascular disease (CCI). See Section 4.3.3.
[0036] In other specific embodiments, the ECM compositions disclosed herein are administered to a subject in a body cavity. To seal, fill and / or otherwise treat voids Used, see section 4.3.4.
[0037] In other specific embodiments, the ECM compositions disclosed herein are Used for tissue bulking, see section 4.3.5.
[0038] In other specific embodiments, the ECM compositions disclosed herein are Used to treat urinary incontinence, see section 4.3.6.
[0039] In other specific embodiments, the ECM compositions disclosed herein are Used to treat vesicoureteral reflux, see section 4.3.7.
[0040] In other specific embodiments, the ECM compositions disclosed herein are Used to treat gastroesophageal reflux disease, see section 4.3.8.
[0041] In other specific embodiments, the ECM compositions disclosed herein are For use in the treatment of diseases, disorders or other abnormal conditions affecting one or both vocal cords and / or the larynx See section 4.3.9.
[0042] In other specific embodiments, the ECM compositions disclosed herein are Used in the management or treatment of glottic incompetence. Section 4.3.10 Please refer to.
[0043] In other specific embodiments, the ECM compositions disclosed herein are Used in bioengineering. See Section 4.3.11 stomach.
[0044] In other specific embodiments, the ECM compositions disclosed herein are used for cosmetic purposes, e.g. For example, augmenting a subject's skin for cosmetic purposes (e.g., to make the subject appear more youthful). This is used for the following purposes: making something visible (see Section 4.3.12).
[0045] In other aspects, disclosed herein are ECM compositions disclosed herein. The kits disclosed herein are generally suitable for use by practitioners of ordinary skill in the art. The ECM compositions disclosed herein are packaged in a container convenient for distribution to a patient. Please refer to. [Brief description of the drawings]
[0046] 3.1 Brief description of the drawings [Figure 1] 1A-1F: Tissue reactivity to ECM sheets prepared according to the methods described herein compared to tissue reactivity to porcine urinary bladder matrix after implantation in albino New Zealand White rabbits. At 1 week post-implantation, tissue adjacent to the urinary bladder matrix (UBM) sheet shows clear signs of granulation and inflammatory response (FIG. 1A), whereas tissue adjacent to the ECM sheet shows scattered muscle tissue with slight infiltration of granulocytes (FIG. 1B). At 2 and 4 weeks, granulation is more pronounced adjacent to the UBM sheet (FIGS. 1C and 1E), whereas tissue adjacent to the ECM sheet appears substantially devoid of granulation and normal (FIGS. 1D and 1F). [Diagram 2]Figures 2A-2F: Shows tissue reactivity to ECM particles prepared according to the methods described herein compared to tissue reactivity to MATRISTEM MICROMATRIX® after implantation in albino New Zealand White rabbits. At 1 week after implantation, the ECM particles show some granulation indicative of inflammation (Figure 2B), but to a significantly lesser extent than the UBM particles (Figure 2A). At 2 and 4 weeks, the ECM particles show a significant reduction in granulation (Figures 2D and 2F), compared to the UBM particles showing substantial inflammation at 2 and 4 weeks (Figures 2C and 2E). [Diagram 3] 3A-3F: Shows tissue reactivity to an ECM flowable matrix prepared according to the methods described herein compared to a bovine derived wound matrix product (INTEGRA™ Flowable) after implantation in an albino New Zealand White rabbit. The bovine derived wound matrix product (INTEGRA™ Flowable) shows granulation at week 1 (FIG. 3A) followed by scarring at weeks 2 and 4 (light areas in FIGS. 3C and 3E). On the other hand, the ECM flowable matrix shows an inflammatory response essentially only in the first week (FIG. 3B) followed by almost complete recovery at weeks 2 and 4 (FIGS. 3D and 3F). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0047] 4. Detailed Description of the Invention As used herein, the terms extracellular matrix (ECM) composition (see 4.1) and extracellular matrix (EC M) A method for producing the composition (see 4.2) is disclosed herein. Uses of the ECM compositions disclosed herein (see 4.3) and A kit containing the composition is disclosed (see Section 5).
[0048] 4.1. Extracellular matrix composition In one embodiment, what is disclosed herein is a placental tissue (e.g., human placental tissue). ) is an extracellular matrix (ECM) composition prepared using the ECM described herein. The composition may contain ECM components, such as collagen and elastin, as described in the art. It is included in an amount different from that in known ECM compositions.
[0049] In some embodiments, the ECM compositions disclosed herein comprise about 30% to 6 0% collagen and about 10% to about 35% elastin. The term "about" as used herein refers to an amount that is 10% more or less than the particular number. In addition, Such ECM compositions disclosed herein can be used in a variety of applications, including (i) assays using, for example, ELISA (enzyme-linked immunosorbent assays) Very low amounts of fibronectin (e.g., less than 0.1% fibronectin) as measured by ironectin), (ii) undetectable or undetectable amounts, for example, as measured by ELISA. laminin, and / or undetectable or non-detectable, for example, by ELISA. Contains large amounts of glycosaminoglycans.
[0050] In some embodiments, the ECM compositions disclosed herein comprise about 30% to 7 2% collagen and about 10% to about 35% elastin. CM compositions can be (i) measured in very small amounts, for example by ELISA. (ii) fibronectin (e.g., less than 0.1% fibronectin), e.g. Laminin measured by immunoassay (e.g., less than 0.1% laminin), e.g., ELISA Glycosaminoglycans measured by the method (e.g., less than 0.1% glycosaminoglycans) (iii) undetectable or undetectable amounts of cytokines; (iv) undetectable (v) undetectable or undetectable amounts of growth factors, and / or (v) undetectable or undetectable amounts of de It may contain oxycholic acid.
[0051] The ECM compositions disclosed herein have properties suitable for therapeutic / medical use. In particular, the ECM compositions disclosed herein are sterile and acellular (e.g., 99% acellular) and / or free of cellular debris (e.g. In certain embodiments, the methods disclosed herein are The ECM composition to be used may be free of cytokines or may be assayed, for example, by ELISA. In some embodiments, the present invention further comprises an inducible amount of cytokines. The ECM compositions disclosed in are devoid of residual reagents. The composition contains undetectable amounts of the reagents used in the preparation of the composition. In certain embodiments, the ECM compositions disclosed herein contain minimal amounts of nucleic acids (e.g. For example, ~41-171ng / mg for dry products) and endotoxin (e.g., <0.25EU ).
[0052] Another advantageous property of the ECM compositions disclosed herein is their water absorbency. In some embodiments, the ECM compositions disclosed herein contain up to 150% of their own weight. Absorbs %-225% of water.
[0053] In certain embodiments, the ECM compositions disclosed herein are about 34-53% collagen. In another particular embodiment, the EC comprises about 13-29% elastin and about 13-29% erythrocyte segregation. The M composition is obtained from placental tissue, e.g., human placental tissue. In the present invention, the ECM composition is obtained from placental chorion, for example from human placenta. In other specific embodiments, the ECM composition contains very little fibronectin. For example, less than 0.1% fibronectin, less than 0.01% fibronectin In certain other embodiments, the composition comprises less than 0.001% fibronectin. The ECM composition contains no laminin or an undetectable amount of laminin. In an embodiment, the ECM composition is free of or has undetectable glycosaminoglycans. In certain other embodiments, the ECM composition comprises a glycosaminoglycan in an amount sufficient to contains very little fibronectin, e.g., less than 0.1% fibronectin, Contains less than 0.01% fibronectin or less than 0.001% fibronectin, Contains no laminin or undetectable amounts of laminin and no glycosaminoglycans Contains little or no detectable amounts of glycosaminoglycans.
[0054] In other specific embodiments, the ECM compositions disclosed herein comprise about 35-55% In another particular embodiment, the composition comprises collagen and about 10-30% elastin. The ECM composition can be obtained from placental tissue, e.g., human placental tissue. In some embodiments, the ECM composition is derived from placental chorion, e.g., chorion from a human placenta. In another specific embodiment, the ECM composition contains very little fibronectin. For example, less than 0.1% fibronectin, less than 0.01% fibronectin In certain other embodiments, the composition comprises fibronectin or less than 0.001% fibronectin. The ECM composition contains no laminin or an undetectable amount of laminin. In certain embodiments, the ECM composition is free of glycosaminoglycans or is In certain other embodiments, the ECM composition comprises a non-reducible amount of glycosaminoglycans. The composition contains very little fibronectin, e.g., less than 0.1% fibronectin. containing less than 0.01% fibronectin or less than 0.001% fibronectin , containing no laminin or undetectable amounts of laminin, and containing glycosaminoglycans Contains no or undetectable amounts of glycosaminoglycans.
[0055] Certain embodiments disclosed herein contain about 35-72% collagen and about 1 The ECM composition contains 5-25% elastin. Certain embodiments include an E collagen composition that contains about 40-70% collagen and about 15-25% elastin. In another specific embodiment, the composition is a collagen composition comprising 40-70% collagen. In another particular embodiment, the composition comprises 15-22% elastin and 15-22% glycerin. , 43-68% collagen and 18-21% elastin. In the present invention, the ECM composition contains fibronectin, e.g., less than 0.1% fibronectin. fibronectin, less than 0.05% fibronectin, less than 0.01% fibronectin, <0.001% fibronectin, 0.001 to 0.1% fibronectin, 0 .001 to 0.05% fibronectin, 0.001 to 0.01% fibronectin 0.01 to 0.1% fibronectin, or 0.01 to 0.05% In another specific embodiment, the ECM composition comprises laminin, For example, less than 0.1% laminin, less than 0.05% laminin, less than 0.01% laminin Laminin, less than 0.001% Laminin, 0.001 to 0.1% Laminin, 0.001 to 0.05% laminin, 0.001 to 0.01% laminin, 0.01 to 0.1% laminin, or 0.01 to 0.05% laminin. The ECM composition may include glycosaminoglycans, e.g., less than 0.1% glycosaminoglycans. Glycosaminoglycans, less than 0.05% glycosaminoglycans, less than 0.01% glycosaminoglycans Glycans, less than 0.001% glycosaminoglycans, 0.001 to 0.1% glycosaminoglycans Glycosaminoglycans, 0.001 to 0.05% Glycosaminoglycans, 0.001 to 0 .01% glycosaminoglycans, 0.01 to 0.1% glycosaminoglycans, or In another particular embodiment, the composition comprises 0.01 to 0.05% glycosaminoglycan. The ECM composition does not include cytokines, growth factors, and / or deoxycholic acid. or undetectable amounts of cytokines, growth factors and / or deoxycholic acid. In some embodiments, the ECM composition includes fibronectin, e.g., 0.1 % Fibronectin, 0.05% Fibronectin, 0.01% Fibronectin Fibronectin, less than 0.001% fibronectin, 0.001 to 0.1% fibrinogen Lonectin, 0.001 to 0.05% Fibronectin, 0.001 to 0.01% of fibronectin, 0.01 to 0.1% fibronectin, or 0.01 to 0. 0.05% fibronectin and laminin, e.g., less than 0.1% laminin; Less than 0.05% laminin, less than 0.01% laminin, less than 0.001% laminin, 0.001 to 0.1% laminin, 0.001 to 0.05% laminin, 0.001 to 0.01% laminin, 0.01 to 0.1% laminin, or 0.01 to 0.0 Contains 5% laminin and contains glycosaminoglycans, e.g., less than 0.1% glycosaminoglycans. Glycosaminoglycans, less than 0.05% glycosaminoglycans, less than 0.01% glycosaminoglycans Glycans, less than 0.001% glycosaminoglycans, 0.001 to 0.1% glycosaminoglycans Glycosaminoglycans, 0.001 to 0.05% Glycosaminoglycans, 0.001 to 0 .01% glycosaminoglycans, 0.01 to 0.1% glycosaminoglycans, or Contains 0.01 to 0.05% glycosaminoglycans, plus cytokines, growth factors, and Contains no or undetectable amounts of cytokines, growth factors, and / or deoxycholic acid and / or deoxycholic acid. In certain other embodiments, the antibody is obtained from placental tissue, e.g., human placental tissue. The ECM composition is obtained from the placental chorion, e.g., the chorionic plate of the placenta. For example, the chorionic plate derived from the human placenta.
[0056] Other specific embodiments disclosed herein include a collagen composition comprising about 50-60% collagen and The ECM composition comprises about 10-20% elastin. The ECM composition is obtained from placental tissue, for example, human placental tissue. In the present invention, the ECM composition is obtained from placental chorion, for example, chorion from a human placenta. In other specific embodiments, the ECM composition contains very little fibronectin. For example, less than 0.1% fibronectin, less than 0.01% fibronectin In certain other embodiments, the composition comprises less than 0.001% fibronectin. The ECM composition contains no laminin or an undetectable amount of laminin. In an embodiment, the ECM composition is free of or has undetectable glycosaminoglycans. In certain other embodiments, the ECM composition comprises a glycosaminoglycan in an amount sufficient to contains very little fibronectin, e.g., less than 0.1% fibronectin, Contains less than 0.01% fibronectin or less than 0.001% fibronectin, Contains no laminin or undetectable amounts of laminin and no glycosaminoglycans Contains little or no detectable amounts of glycosaminoglycans.
[0057] Other specific embodiments disclosed herein include a collagen composition comprising about 45-55% collagen and In certain embodiments, the ECM composition comprises about 15-25% elastin. The ECM composition is obtained from placental tissue, for example, human placental tissue. In the present invention, the ECM composition is obtained from placental chorion, for example, chorion from a human placenta. In other specific embodiments, the ECM composition contains very little fibronectin. For example, less than 0.1% fibronectin, less than 0.01% fibronectin In certain other embodiments, the composition comprises less than 0.001% fibronectin. The ECM composition contains no laminin or an undetectable amount of laminin. In an embodiment, the ECM composition is free of or has undetectable glycosaminoglycans. In certain other embodiments, the ECM composition comprises a glycosaminoglycan in an amount sufficient to contains very little fibronectin, e.g., less than 0.1% fibronectin, Contains less than 0.01% fibronectin or less than 0.001% fibronectin, Contains no laminin or undetectable amounts of laminin and no glycosaminoglycans Contains little or no detectable amounts of glycosaminoglycans.
[0058] Other specific embodiments disclosed herein include a collagen composition comprising about 40-50% collagen and In certain embodiments, the ECM composition comprises about 20-30% elastin. The ECM composition is obtained from placental tissue, for example, human placental tissue. In the present invention, the ECM composition is obtained from placental chorion, for example, chorion from a human placenta. In other specific embodiments, the ECM composition contains very little fibronectin. For example, less than 0.1% fibronectin, less than 0.01% fibronectin In certain other embodiments, the composition comprises less than 0.001% fibronectin. The ECM composition contains no laminin or an undetectable amount of laminin. In an embodiment, the ECM composition is free of or has undetectable glycosaminoglycans. In certain other embodiments, the ECM composition comprises a glycosaminoglycan in an amount sufficient to contains very little fibronectin, e.g., less than 0.1% fibronectin, Contains less than 0.01% fibronectin or less than 0.001% fibronectin, Contains no laminin or undetectable amounts of laminin and no glycosaminoglycans Contains little or no detectable amounts of glycosaminoglycans.
[0059] Other specific embodiments disclosed herein include a collagen composition comprising about 30-40% collagen and In certain embodiments, the ECM composition comprises about 25-35% elastin. The ECM composition is obtained from placental tissue, for example, human placental tissue. In the present invention, the ECM composition is obtained from placental chorion, for example, chorion from a human placenta. In other specific embodiments, the ECM composition contains very little fibronectin. For example, less than 0.1% fibronectin, less than 0.01% fibronectin In certain other embodiments, the composition comprises less than 0.001% fibronectin. The ECM composition contains no laminin or an undetectable amount of laminin. In an embodiment, the ECM composition is free of or has undetectable glycosaminoglycans. In certain other embodiments, the ECM composition comprises a glycosaminoglycan in an amount sufficient to contains very little fibronectin, e.g., less than 0.1% fibronectin, Contains less than 0.01% fibronectin or less than 0.001% fibronectin, Contains no laminin or undetectable amounts of laminin and no glycosaminoglycans Contains little or no detectable amounts of glycosaminoglycans.
[0060] Other specific embodiments disclosed herein include a collagen composition comprising about 34-43% collagen and In certain embodiments, the ECM composition comprises about 16-24% elastin. The ECM composition is obtained from placental tissue, for example, human placental tissue. In the present invention, the ECM composition is obtained from placental chorion, for example, chorion from a human placenta. In other specific embodiments, the ECM composition contains very little fibronectin. For example, less than 0.1% fibronectin, less than 0.01% fibronectin In certain other embodiments, the composition comprises less than 0.001% fibronectin. The ECM composition contains no laminin or an undetectable amount of laminin. In an embodiment, the ECM composition is free of or has undetectable glycosaminoglycans. In certain other embodiments, the ECM composition comprises a glycosaminoglycan in an amount sufficient to contains very little fibronectin, e.g., less than 0.1% fibronectin, Contains less than 0.01% fibronectin or less than 0.001% fibronectin, Contains no laminin or undetectable amounts of laminin and no glycosaminoglycans Contains little or no detectable amounts of glycosaminoglycans.
[0061] Other specific embodiments disclosed herein include a collagen composition comprising about 37-42% collagen and In certain embodiments, the ECM composition comprises about 16-24% elastin. The ECM composition is obtained from placental tissue, for example, human placental tissue. In the present invention, the ECM composition is obtained from placental chorion, for example, chorion from a human placenta. In other specific embodiments, the ECM composition contains very little fibronectin. For example, less than 0.1% fibronectin, less than 0.01% fibronectin In certain other embodiments, the composition comprises less than 0.001% fibronectin. The ECM composition contains no laminin or an undetectable amount of laminin. In an embodiment, the ECM composition is free of or has undetectable glycosaminoglycans. In certain other embodiments, the ECM composition comprises a glycosaminoglycan in an amount sufficient to contains very little fibronectin, e.g., less than 0.1% fibronectin, Contains less than 0.01% fibronectin or less than 0.001% fibronectin, Contains no laminin or undetectable amounts of laminin and no glycosaminoglycans Contains little or no detectable amounts of glycosaminoglycans.
[0062] Other specific embodiments disclosed herein include about 30-70%, 30-60%, 30-50%, 30-40%, 30-35%, 34-43%, 35-72%, 35-40 %, 37-42%, 40-70%, 40-60%, 40-50%, 40-45%, 40- 65%, 43-68%, 45-50%, 50-55%, or 55-60% collagen and and approximately 10-30%, 10-20%, 10-15%, 15-25%, 15-22%, 15- 20%, 16-24%, 17-24%, 18-21%, 18-20%, 20-24%, 2 ECM containing 0-30%, 20-25%, 25-30%, or 30-35% elastin In certain embodiments, the ECM composition is a composition comprising placental tissue, e.g., human In another specific embodiment, the ECM composition is obtained from placental tissue. The chorion may be obtained from, for example, the chorionic plate of the placenta. The chorion may be, for example, the chorionic plate from the human placenta. In certain other embodiments, the ECM composition comprises a very small amount of fibroblasts. Fibronectin, e.g., less than 0.1% fibronectin, less than 0.05% fibronectin, nectin, less than 0.01% fibronectin, less than 0.001% fibronectin In some embodiments, the ECM composition comprises 0.001 to 0.1% fumarate. Fibronectin, 0.001 to 0.05% Fibronectin, 0.001 to 0.0 1% fibronectin, 0.01 to 0.1% fibronectin, or 0.01 to In certain other embodiments, the ECM composition comprises 0.05% fibronectin. In certain other embodiments, the laminin-containing IgG antibody is free of laminin or contains an undetectable amount of laminin. In this case, the ECM composition contains very little laminin, e.g., less than 0.1% laminin. less than 0.05% laminin, less than 0.01% laminin, or less than 0.001% In certain other embodiments, the ECM composition comprises laminin, e.g. For example, 0.001 to 0.1% laminin, 0.001 to 0.05% laminin, 0. 001 to 0.01% laminin, 0.01 to 0.1% laminin, or 0.01 to In another specific embodiment, the ECM composition comprises 0.05% laminin. Contains no glycosaminoglycans or undetectable amounts of glycosaminoglycans. In certain embodiments, the ECM composition contains minimal amounts of glycosaminoglycans. , e.g., less than 0.1% glycosaminoglycans, less than 0.05% glycosaminoglycans Glycosaminoglycans, less than 0.01% Glycosaminoglycans, less than 0.001% In other specific embodiments, the ECM composition comprises glycosaminoglycans. , e.g., 0.001 to 0.1% glycosaminoglycans, 0.001 to 0.05% glycosaminoglycans, 0.001 to 0.01% glycosaminoglycans, 0.01 to 0.1% glycosaminoglycan, or 0.01 to 0.05% glycosaminoglycan In certain other embodiments, the ECM composition comprises a minimal amount of fibronectin. Fibronectin, e.g., less than 0.1% fibronectin, less than 0.01% fibronectin, Nectin, or less than 0.001% fibronectin, and no laminin or Contains undetectable amounts of laminin and contains no or undetectable amounts of glycosaminoglycans In some embodiments, the ECM composition comprises a fibrinogen. For example, less than 0.1% fibronectin, less than 0.05% fibrinogen Fibronectin, less than 0.01% Fibronectin, less than 0.001% Fibronectin , 0.001 to 0.1% fibronectin, 0.001 to 0.05% fibronectin 0.001 to 0.01% fibronectin, 0.01 to 0.1% fibrin fibronectin, or 0.01 to 0.05% fibronectin, and laminin; For example, less than 0.1% laminin, less than 0.05% laminin, less than 0.01% laminin Laminin, less than 0.001% Laminin, 0.001 to 0.1% Laminin, 0.001 to 0.05% laminin, 0.001 to 0.01% laminin, 0.01 to 0.1% Laminin or 0.01 to 0.05% laminin and glycosaminoglycan , e.g., less than 0.1% glycosaminoglycans, less than 0.05% glycosaminoglycans Glycosaminoglycans, less than 0.01% Glycosaminoglycans, less than 0.001% , 0.001 to 0.1% glycosaminoglycans, 0.001 to 0.05% glycosaminoglycans Glycosaminoglycans, 0.001 to 0.01% Glycosaminoglycans, 0.01 to 0. Contains 1% glycosaminoglycans or 0.01 to 0.05% glycosaminoglycans In addition, the composition contains no or detectable cytokines, growth factors and / or deoxycholic acid. The antibody contains ineffective amounts of cytokines, growth factors and / or deoxycholic acid.
[0063] Other specific embodiments disclosed herein include about 30%, about 35%, about 40%, About 45%, about 50%, about 55%, about 60%, about 65%, about 70% or about 72% collagen and about 10%, about 15%, about 18%, about 20%, about 25%, about 30% or about 35% In a specific embodiment, the ECM composition comprises: In certain other embodiments, the E. coli is obtained from placental tissue, e.g., human placental tissue. The CM composition is obtained from the chorion of the placenta, e.g., the chorionic plate of the placenta. For example, the chorionic plate from human placenta. In another specific embodiment, the ECM composition is , containing very small amounts of fibronectin, e.g., less than 0.1% fibronectin, 0 Less than .05% Fibronectin, Less than 0.01% Fibronectin, Less than 0.001% In some embodiments, the ECM composition comprises 0. 001 to 0.1% fibronectin, 0.001 to 0.05% fibronectin , 0.001 to 0.01% fibronectin, 0.01 to 0.1% fibronectin In certain other embodiments, the antibody comprises 0.01 to 0.05% fibronectin. In this case, the ECM composition contains no laminin or an undetectable amount of laminin. In certain other embodiments, the ECM composition contains very little laminin, e.g. For example, less than 0.1% laminin, less than 0.05% laminin, less than 0.01% laminin, or less than 0.001% laminin. The product contains laminin, e.g., 0.001 to 0.1% laminin, 0.001 to 0. 05% laminin, 0.001 to 0.01% laminin, 0.01 to 0.1% laminin In certain other embodiments, the antibody comprises 0.01 to 0.05% laminin. The ECM composition contains no glycosaminoglycans or contains undetectable amounts of glycosaminoglycans. In certain other embodiments, the ECM composition contains very little glycan. Containing glycosaminoglycans, e.g., less than 0.1% glycosaminoglycans, less than 0.05% Glycosaminoglycans: Less than 0.01% Glycosaminoglycans: Less than 0.001% In another specific embodiment, the ECM composition comprises glycosaminoglycans. Glycosaminoglycans, e.g., 0.001 to 0.1% glycosaminoglycans, 0 .001 to 0.05% glycosaminoglycans, 0.001 to 0.01% glycosaminoglycans glycosaminoglycan, 0.01 to 0.1% glycosaminoglycan, or 0.01 to 0.0 In another specific embodiment, the ECM composition comprises 5% glycosaminoglycans. , containing very small amounts of fibronectin, e.g., less than 0.1% fibronectin, 0 Contains less than 0.01% fibronectin, or less than 0.001% fibronectin, Contains no laminin or undetectable amounts of laminin and no glycosaminoglycans In some embodiments, the glycosaminoglycans are in a low or undetectable amount. The ECM composition includes fibronectin, e.g., less than 0.1% fibronectin, Fibronectin <0.05%, Fibronectin <0.01%, 0.001% Fibronectin, 0.001 to 0.1% Fibronectin, 0.001 to 0.05% fibronectin, 0.001 to 0.01% fibronectin, 0.0 1 to 0.1% fibronectin, or 0.01 to 0.05% fibronectin containing laminin, e.g., less than 0.1% laminin, less than 0.05% laminin, Less than 0.01% laminin, less than 0.001% laminin, 0.001 to 0.1% laminin laminin, 0.001 to 0.05% laminin, 0.001 to 0.01% laminin, Contains 0.01 to 0.1% laminin, or 0.01 to 0.05% laminin, and Containing glycosaminoglycans, e.g., less than 0.1% glycosaminoglycans, less than 0.05% Glycosaminoglycans: Less than 0.01% Glycosaminoglycans: Less than 0.001% glycosaminoglycans, 0.001 to 0.1% glycosaminoglycans, 0.001 to 0.05% glycosaminoglycans, 0.001 to 0.01% glycosaminoglycans cans, 0.01 to 0.1% glycosaminoglycans, or 0.01 to 0.05% Glycosaminoglycans, in addition to cytokines, growth factors and / or deoxycholate Acid-free or undetectable amounts of cytokines, growth factors and / or deoxycholic acid Includes.
[0064] Other specific embodiments disclosed herein include collagen at about 31%, about 32%, , approx. 33%, approx. 34%, approx. 35%, approx. 36%, approx. 37%, approx. 38%, approx. 39%, approx. 40% , 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48% , 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56% ,About 57%,About 58%,About 59%,60%,61%,62%,63%,64%,65%, Contains 66%, 67%, 68%, 69%, 70%, 71%, or 72% elastin and approximately 0%, approx. 11%, approx. 12%, approx. 13%, approx. 14%, approx. 15%, approx. 16%, approx. 17%, approx. 8%, about 19%, about 20%, about 21%, about 22%, about 23%, about 24%, about 25%, about 2 6%, about 27%, about 28%, about 29%, about 30%, about 31%, about 32%, about 33%, about 3 In certain embodiments, the ECM composition comprises 4% or 35%. In certain other embodiments, the method comprises the steps of: obtaining the placental tissue, e.g., human placental tissue; The ECM composition is obtained from the placental chorion, e.g., the chorionic plate of the placenta. For example, the chorionic plate from human placenta. In another specific embodiment, the ECM composition The article contains very little fibronectin, e.g., less than 0.1% fibronectin. , less than 0.05% fibronectin, less than 0.01% fibronectin, 0.001 In some embodiments, the ECM composition comprises less than 5% fibronectin. 0.001 to 0.1% fibronectin, 0.001 to 0.05% fibronectin 0.001 to 0.01% fibronectin, 0.01 to 0.1% fibronectin nectin, or 0.01 to 0.05% fibronectin. The ECM composition does not contain laminin or contains an undetectable amount of laminin. In other specific embodiments, the ECM composition comprises minimal amounts of laminin, For example, less than 0.1% laminin, less than 0.05% laminin, less than 0.01% laminin In certain other embodiments, the ECM comprises less than 0.001% laminin. The composition includes laminin, e.g., 0.001 to 0.1% laminin, 0.001 to 0.05% laminin, 0.001 to 0.01% laminin, 0.01 to 0.1% laminin, or 0.01 to 0.05% laminin. The ECM composition is free of glycosaminoglycans or contains undetectable amounts of glycosaminoglycans. In another specific embodiment, the ECM composition comprises a very small amount of aminoglycan. Glycosaminoglycans, e.g., less than 0.1% glycosaminoglycans, 0.05 % glycosaminoglycans, less than 0.01% glycosaminoglycans, less than 0.001% In certain other embodiments, the ECM composition comprises less than about 100% glycosaminoglycans. Glycosaminoglycans, e.g., 0.001 to 0.1% glycosaminoglycans , 0.001 to 0.05% glycosaminoglycans, 0.001 to 0.01% glycol Glycosaminoglycans, 0.01 to 0.1% Glycosaminoglycans, or 0.01 to 0 In certain other embodiments, the ECM composition comprises 0.05% glycosaminoglycans. The article contains very little fibronectin, e.g., less than 0.1% fibronectin. , less than 0.01% fibronectin, or less than 0.001% fibronectin , containing no laminin or undetectable amounts of laminin, and containing glycosaminoglycans In some embodiments, the glycosaminoglycan is free of or contains an undetectable amount of glycosaminoglycans. The ECM composition may contain fibronectin, e.g., less than 0.1% fibronectin. Fibronectin, less than 0.05% Fibronectin, less than 0.01% Fibronectin, 0.00 <1% Fibronectin, 0.001 to 0.1% Fibronectin, 0.001 to 0.05% fibronectin, 0.001 to 0.01% fibronectin, 0 .01 to 0.1% fibronectin, or 0.01 to 0.05% fibronectin Contains laminin, e.g., less than 0.1% laminin, less than 0.05% laminin Laminin, less than 0.01% Laminin, less than 0.001% Laminin, 0.001 to 0.1% laminin, 0.001 to 0.05% laminin, 0.001 to 0.01% laminin 0.01 to 0.1% laminin, or 0.01 to 0.05% laminin, Glycosaminoglycans, e.g., less than 0.1% glycosaminoglycans, 0.05 % glycosaminoglycans, less than 0.01% glycosaminoglycans, less than 0.001% Less than 0.001 to 0.1% glycosaminoglycans, 0.0 0.01 to 0.05% glycosaminoglycans, 0.001 to 0.01% glycosaminoglycans Glycans, 0.01 to 0.1% glycosaminoglycans, or 0.01 to 0.05% In addition, the glycosaminoglycans may be Contains no or undetectable amounts of cytokines, growth factors and / or deoxycholic acid. Contains cyclic acid.
[0065] In some embodiments, the collagen in the ECM compositions described herein is It contains telopeptide collagen, i.e., it is a component of the collagen. In some embodiments, the collagen in the ECM compositions described herein is It contains atelopeptide collagen, i.e., it is a component of the In some cases, the collagen is made up of telopeptide collagen and atelopeptide collagen. .
[0066] The first type of collagen in the ECM compositions disclosed herein is type I collagen ( In some embodiments, the ECM disclosed herein is The collagen in the composition is at least 60%, at least 65%, at least Contains 70%, at least 75%, at least 80%, or more than 80% type I collagen In some embodiments, the collagen in the ECM compositions disclosed herein is By dry weight, 50% to 70% type I collagen, 60% to 80% type I collagen, or 70% to 90% type I collagen. The collagen in the ECM compositions shown comprises 60% to 80% type I collagen.
[0067] In some embodiments, the collagen in the ECM compositions disclosed herein is For example, type I collagen may be included as well as type III collagen and / or type IV collagen. As mentioned above, it contains a mixture of multiple types of collagen.
[0068] In certain embodiments, the collagen in the ECM compositions disclosed herein is equivalent to Contains a large amount of type I collagen (e.g., 60%-80% type I collagen) and also type III collagen Collagen is also included. For example, in addition to type I collagen, the ECM compositions disclosed herein include The collagen in the preparation is 1% to 5% type III collagen, 5% to 10% type I collagen, and It may contain type II collagen, or 1% to 10% type III collagen, or The collagen in the ECM compositions disclosed herein is present in an amount of about 1%, about 2%, about 3% by dry weight. , about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10% of type III collagen May include gen.
[0069] In other specific embodiments, the collagen in the ECM compositions disclosed herein is Contains significant amounts of type I collagen (e.g., 60%-80% type I collagen) and For example, in addition to collagen type I, the ECMs disclosed herein also include collagen type V. The collagen in the composition is, by dry weight, 1% to 5% type IV collagen, 5% to 10% % type IV collagen, or 1% to 10% type IV collagen, or Collagen in the ECM compositions disclosed herein may be present in an amount of about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, or about 10% of Type IV It may contain largen.
[0070] In other specific embodiments, the collagen in the ECM compositions disclosed herein is Contains significant amounts of type I collagen (e.g., 60%-80% type I collagen) and also type II It also includes type I collagen and type IV collagen. For example, in addition to type I collagen, The collagen in the ECM composition disclosed in collagen, 5% to 10% type III collagen, or 1% to 10% type III collagen Alternatively, the collagen in the ECM compositions disclosed herein may comprise at least about 100% by dry weight. About 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, if and (ii) may contain, by dry weight, 1% to 5% type I collagen. Type V collagen, 5% to 10% type IV collagen, or 1% to 10% type IV collagen The collagen in the ECM compositions disclosed herein may be dried. By dry weight, approximately 1%, approximately 2%, approximately 3%, approximately 4%, approximately 5%, approximately 6%, approximately 7%, approximately 8%, approximately 9% , or about 10% type IV collagen.
[0071] In some embodiments, the collagen in the ECM compositions disclosed herein is For example, the crosslinking agent is glutaraldehyde (e.g., See, for example, U.S. Patent Nos. 4,852,640, 5,428,022, 5,660,692 and 5,008,116. The contents of these patents are incorporated herein by reference in their entireties. , 1,4-butanediol diglycidyl ether, and genipin (see, e.g., U.S. Pat. No. 5,313,933). See U.S. Patent Application No. 2003 / 0049301, the contents of which are incorporated herein by reference in their entirety. Further examples of crosslinking agents and methods for crosslinking collagen are included in the US Pat. US Patent Nos. 5,880,242 and 6,117,979, and Zeeman et al., 2000, J Biomed Mater Res. 51(4):541-8), van Wachem et al. (2000, J Biomed Mater Res. 53(1):18-27), van Wachem et al. (1999, J Biom ed Mater Res. 47(2):270-7), Zeeman et al. (1999, J Biomed Mat Res. 46(3):424-33) and Zeeman et al. (1999, Biomaterials 20(10):921-31, the contents of which are incorporated by reference in their entirety. The present invention is hereby incorporated by reference in its entirety.
[0072] 4.1.1 Preparation The ECM compositions disclosed herein can be prepared by a variety of methods. The type of article can be selected based, for example, on the intended use of the ECM composition.
[0073] In certain embodiments, the ECM compositions disclosed herein are prepared as flowable matrices. The pharmaceutical composition is prepared in a form that can be administered, for example, by using a syringe. Shown is a syringe containing an ECM composition as described herein. In some embodiments, the ECM composition of the flowable matrix disclosed herein is water. or in phosphate buffered saline, e.g., as a solution or suspension, e.g., as a mouthwash. In solution (e.g., as a flowable matrix), the ECM compositions disclosed herein can It may be present at any concentration useful to one of skill in the art. The fluid matrix ECM composition disclosed in g / ml, 150-250mg / ml, 0.1-100mg / ml, 1-100mg / m l, 1-75mg / ml, 1-50mg / ml, 1-40mg / ml, 10-40mg / In some embodiments, the ECM comprises 20-40 mg / ml of ECM. The flowable matrix ECM compositions disclosed herein may be in the form of a matrix of about 5 mg / ml, 10 mg / ml, 15 mg / ml, or 20 mg / ml. / ml, 20mg / ml, 25mg / ml, 30mg / ml, 35mg / ml, 40mg / ml, 45mg / ml, 50mg / ml ECM, 75mg / ml, 100mg / ml , 125mg / ml, 150mg / ml, 175mg / ml, 200mg / ml, 225 250mg / ml, 275mg / ml, or 300mg / ml ECM In certain embodiments, disclosed herein is an ECM at 200 mg / ml. In some embodiments, the present invention provides a flowable matrix ECM composition comprising: The flowable matrix ECM composition is prepared using the methods described herein and is a lyophilized The ECM may be prepared by one skilled in the art using dried and powdered ECM. The dried and powdered ECM may be provided in the form of a kit, e.g., in a saline solution. The freeze-dried and powdered ECM can then be suspended in a suitable suspension solution by one of ordinary skill in the art. By suspending the ECM in the suspension solution, a flowable matrix ECM composition can be easily produced. can.
[0074] In certain other embodiments, the ECM compositions disclosed herein are provided in, for example, powder form. When in the form of particles, the ECM compositions disclosed herein may be prepared as particles, such as in the form of particles. , vials (e.g., glass vials), or any other suitable container for storing particles. The ECM compositions disclosed herein, when provided as particles, may be prepared in a container. The may be provided in the container at any concentration useful to one of skill in the art. In the present specification, the particulate ECM composition may be administered in an amount of 200-300 mg, 100-200 mg, or mg, 150-250mg, 50-100mg, 25-50mg, 10-25mg, 5- In some embodiments, some of the samples contain 10 mg of ECM, or 1-5 mg of ECM. In embodiments, the flowable matrix ECM compositions disclosed herein are about 5 mg, 10 mg, , 15mg, 20mg, 25mg, 30mg, 35mg, 40mg, 45mg, 50mg ECM, approximately 75mg, 100mg, 125mg, 150mg, 175mg, 200mg , 225 mg, 250 mg, 275 mg, or 300 mg of ECM. In an embodiment, disclosed herein is a particulate ECM composition comprising 200 mg of ECM. In another specific embodiment, the particulate ECM composition comprises 100 mg of ECM. It is.
[0075] In other specific embodiments, the ECM compositions disclosed herein can be, for example, planar. It may be prepared as a sheet, such as a solid ECM layer. If it is a sheet, the method disclosed herein may be used. The ECM composition can be formed into sheets of any thickness and dimensions suitable for the intended use. In some embodiments, the ECM sheets disclosed herein can be, for example, 5× They are provided in standard sizes, such as 5 cm or 8 x 8 cm, and can be prepared by a skilled artisan. Such cutting may be performed, for example, to obtain a suitable subsection for the intended use. The size of the composition is, for example, as a wound dressing. In some embodiments, the ECM compositions disclosed herein have a pH of 0.1-0. 15mm, 0.15-0.2mm, 0.1-0.2mm, 0.2-0.25mm, 0.2 It is prepared as sheets having a thickness of 0.5-0.3 mm, or 0.2-0.3 mm. In some embodiments, the ECM compositions disclosed herein are about 0.1 mm, 0.1 Prepared as sheets having thicknesses of 5 mm, 0.2 mm, 0.25 mm, or 0.3 mm In some embodiments, the ECM compositions disclosed herein are formed into a 2×2 cm , 3×3cm sheets, 4×4cm sheets, 5×5cm sheets, 6×6cm sheets Available as 100 x 100 cm sheets, 7x7 cm sheets, 8x8 cm sheets or 9x9 cm sheets. The sheets are made of approximately 0.1-0.15 mm, 0.15-0.2 mm, 0.1-0.2 mm, 0.2-0.25mm, 0.25-0.3mm, or 0.2-0.3mm thickness Yes.
[0076] In some embodiments, the present disclosure provides and laminates comprising at least one ECM sheet. In one embodiment, disclosed herein is a laminate comprising two ECM sheets. In certain embodiments, what is disclosed herein comprises at least one and at least one other planar decellularized tissue (e.g. , decellularized / dehydrated amniotic membrane, or fully decellularized or with a fibroblast layer retained or alternatively, a laminate having a planar artificial tissue. In some embodiments, the laminate comprises multiple ECM sheets, or one or more The ECM sheet and other planar decellularized tissues may be attached to, for example, glue (e.g., natural glue). In the presence of an adhesive such as glue (e.g., fibronectin, fibrin, or synthetic glue) In some embodiments, the laser may be generated by placing the laser in contact with one another. A laminate is made by combining two or more ECM sheets together, or one or more ECM sheets and one or more The tissue may be produced by baking and drying a planar piece of decellularized tissue together.
[0077] 4.1.1.1 Non-ECM compositions In certain embodiments, the ECM compositions disclosed herein comprise a composition that is not normally associated with ECM. It is prepared to contain one or more ingredients that do not
[0078] In one embodiment, the ECM compositions disclosed herein comprise It is combined with a pharma- ceutically or cosmetically acceptable carrier so as to be suitable for administration to a subject. The subject may be, for example, a human subject in need of such administration. These include, but are not limited to, injections, solutions, creams, gels, implants, and potions. Powder, ointment, emulsion, suspension, microsphere, particle, microparticle particle, nanoparticle, liposome, paste, patch, tablet Agents, transdermal delivery devices, sprays, aerosols and other means known to those skilled in the art. Pharmaceutically or cosmetically acceptable carriers The term "pharmaceutical or cosmetically acceptable" refers to a compound that is not soluble in water and is not a soluble in water. "Pharmaceutically or cosmetically acceptable carrier" or "Pharmaceutically or cosmetically acceptable excipient" The term "typically acceptable vehicle" as used herein is intended to mean, but is not limited to, is used to mean any liquid, solid, or semi-solid, including but not limited to , water or saline, gel, cream, ointment, solvent, diluent, liquid ointment base ment base), ointment paste, implant, liposome, micelle, giant micelle Suitable for use in contact with living animal or human tissue, such as blood vessels, and free from adverse physiological reactions It does not cause adverse reactions or cosmetic reactions and does not interact with other components of the composition, such as the ECM, in any adverse manner. This includes those that do not interact with each other.
[0079] In one embodiment, the ECM compositions disclosed herein are capable of releasing an active ingredient. For example, the active ingredient is an active ingredient added to the ECM composition. For example, the ECM compositions disclosed herein may be impregnated with biomolecules during or after production. Examples of biomolecules include, but are not limited to, antibiotics (e.g., clindamycin, damycin, minocycline, doxycycline, gentamicin, etc.), hormones, Long-term factors, anticancer drugs, antifungal drugs, antiviral drugs, analgesics, antihistamines, anti-inflammatory drugs, antiseptic drugs Dyes, elemental silver, antibiotics, bactericidal enzymes (e.g. lysosomes) ), wound healing agents (e.g., cytokines, including but not limited to, PDG F, TGF, thymosin), hyaluronic acid, wound sealants (e.g., thrombin In certain instances, the present invention includes a method for the preparation of a cellular membrane comprising administering ... to a subject, the method comprising administering a cellular membrane to the subject, the cellular membrane being administered to the subject, and the method comprising administering a cellular membrane to the subject. The ECM compositions disclosed herein are impregnated with at least one growth factor. For example, the growth factor is a fibroblast growth factor or an epidermal growth factor. In particular, the ECM compositions disclosed herein may be used to provide specific The specific inhibitors are, for example, membrane receptor inhibitors. These include inhibitors, kinase inhibitors, growth inhibitors, and anti-cancer drugs.
[0080] In some embodiments, the ECM compositions disclosed herein are mixed with a hydrogel. Any hydrogel known to those skilled in the art may be used. The soft hydrogels are described in the following paper, Graham, 1998, Med. Device Technol. 9 (1): pp. 18-22, Peppas et al., 2000, Eur. J. Pharm. Biopharm. 50(1): pp. 27-46; Nguyen et al., 2002, Biomaterials, 23(22): 43 pp. 07-4314, Henincl et al., 2002, Adv. Drug Deliv. Rev 54(1 13-36, Skelhorne et al., 2002, Med. Device. Technol. 13(9): pp. 19-23, or Schmedlen et al., 2002, Biomaterials. s 23: pp. 4325-4332, and any of the hydrogel compositions disclosed therein. In embodiments, the hydrogel is applied over the ECM composition, i.e. For example, a hydrogel may be sprayed onto the ECM composition, and the ECM composition may be sprayed onto the surface of the substrate. The ECM composition may be impregnated into the surface of the composition, immersed in the ECM composition, or soaked in the ECM composition. The CM composition may be applied to the surface of the composition. Hydrogels are water-interactive polymers known in the art. or any water-soluble polymer, including, but not limited to, any polymer. However, polyvinyl alcohol (PVA), polyhydroxyethyl methacrylate, Polyethylene glycol, polyvinylpyrrolidone, hyaluronic acid, dextran n) and their derivatives and analogues.
[0081] 4.1.2 Cells The ECM compositions disclosed herein can be seeded or cultured with one or more types of cells. For example, the cells can be cultured in the ECM compositions described herein. The cells may be cultured and grown as a substrate or grown on or in the ECM compositions described herein. It may be dispersed in the ECM composition (e.g., added to a flowable matrix composition of the ECM). The vendor provides a wide variety of cell types, including both stem and non-stem cell types, known in the art. It is understood that cells can be seeded and / or cultured in the ECM compositions disclosed herein. You will fully understand.
[0082] In some embodiments, the ECM compositions disclosed herein are seeded with stem cells. The stem cells may be any stem cells suitable for a given purpose. The cells may be totipotent or pluripotent stem cells, or progenitor cells. In some embodiments, the ECM compositions disclosed herein are seeded with placental stem cells and / or The placental stem cells are described, for example, in U.S. Pat. Nos. 057,788 and 8,202,703, the disclosures of which are incorporated by reference in their entireties. In certain other embodiments, the methods disclosed herein are encompassed by the present application. The ECM compositions used include embryonic stem cells, embryonic germ cells, mesenchymal stem cells, bone marrow derived stem cells, hematopoietic stem cells, and Progenitor cells (e.g., peripheral blood, fetal blood, placental blood, umbilical cord blood, placental perfusate) ate), somatic stem cells, neural stem cells, hepatic stem cells, pancreatic stem cells , endothelial stem cells, cardiac stem cells, muscle stem cells, adipose stem cells, etc. may be seeded and / or contained. In certain embodiments, the stem cells are human stem cells.
[0083] In some embodiments, the ECM compositions disclosed herein include one or more species. The term "terminally differentiated cells" as used herein refers to cells that are not terminally differentiated. For example, in one embodiment, the ECs disclosed herein are The ECM composition includes a plurality of fibroblasts. Non-stem cells include, but are not limited to, fibroblasts or fibroblast-like cells, dermal cells, These include endothelial cells, epithelial cells, muscle cells, cardiac cells, and pancreatic cells. In the present disclosure, the ECM composition is seeded with two types of non-stem cells, and / or included.
[0084] In some embodiments, the ECM compositions disclosed herein are cultured with cells. The culture is continued for a period of time sufficient for the cells to attach to the ECM composition. According to such embodiments, the ECM composition can be formed into a useful shape. For example, the ECM The composition may be in the form of a sheet, plug, tube, or other shape in which the ECM composition is in contact with the cells. It may be shaped before being touched.
[0085] The ECM composition comprises at least 1×10 6 , 3×10 6 , 1×10 7 , 3×10 7 , 1×10 8 , 3×10 8 , 1×10 9 , 3×10 9 , 1×10 10 , 3×10 10 , 1× 10 11 , 3×10 11 , or 1×10 12 or 1 × 10 6 , 3×10 6 , 1×10 7 , 3×10 7 , 1×10 8 , 3×10 8 , 1×10 9 , 3×10 9 , 1×1 0 10 , 3×10 10 , 1×10 11 , 3×10 11 , or 1×10 12 Less than The cells may be cultured together.
[0086] Characterization Biochemical-based assays known in the art can be used to quantify The protein may be used to confirm the biochemical composition of the ECM composition produced using the method. The content of is determined, for example, by an absorbance assay. The measurement is described, for example, in Layne, E., Spectrophotometric and Turbidimetric Met. hods for Measuring Proteins, Methods in Enzymology 3: pp. 447-455, (1957); Stoscheck, CM, Quantitation of Protein, Methods in Enzymology 1 82: pp. 50-69, (1990)), Scopes, R. K., Analytical Biochemistry 5 9: 277, (1974); and Stoscheck, C M. Quantitation of Proteins. ein, Methods in Enzymology 182: 50-69, (1990). To measure the content of specific proteins, the modified Lowry assay was used. ay), biuret assay, Bradford assay, Bicinchoninic Acid (Smith) Assay (Stochett) Stoscheck, C M. Quantitation of Protein, Methods in Enzymology 182: 50-6 9, (1990)) may be used.
[0087] The total collagen content of the ECM compositions disclosed herein can be, for example, hydroxyproline. Lorin or a quantitative dye-based quantification kit, e.g., Biocolor Ltd. The present invention can be determined using the SIRCOL™ kit from Sigma-Aldrich Co., UK. The type of collagen in the ECM composition can be determined by a suitable assay, such as an ELISA assay. This can be determined using standard methods known in the art.
[0088] The total elastin content of the ECM compositions disclosed herein can be determined, for example, by quantitative dye staining. Dye-based quantification kits, such as the dye-based kits from Biocolor Ltd, UK. It can be determined using a quantitative kit (FASTIN) or the like.
[0089] The total glycosaminoglycan (GAG) content of the ECM compositions disclosed herein is For example, a quantitative dye-based quantification kit (Biocolor Ltd, UK) The GAG content can be determined by ELISA. and can be measured using methods known in the art.
[0090] The total laminin and fibronectin content of the ECM compositions disclosed herein can be, e.g. For example, the ELISA assay can be used to determine the amount of erythrocytes in the blood. For example, a method using a ELISA kit manufactured by Takara Bio Inc. (Shiga, Japan) is used. A kit from the Japan Apan Co., Ltd. is available for the determination of laminin and fibronectin using an ELISA kit. The law, etc.
[0091] The ECM compositions disclosed herein are non-immunogenic and can be administered to a subject, e.g., a human subject. The substance is biocompatible with the tissue of the specimen. As used herein, "biocompatible" refers to the ability to Not toxic, harmful, or causing an immune or immunological reaction; In order to confirm the biocompatibility of the ECM compositions disclosed herein, Such evaluations are known to those of skill in the art and include, but are not limited to, the following: Although not intended to be used for clinical trials, cytotoxicity assays (e.g., ISO MEM elution test), rabbit eye irritation assays, These tests include rabbit eye irritation tests, hemolysis tests, and pyrexia tests.
[0092] The ECM compositions disclosed herein can be prepared sterile, thereby providing a biological Free of contaminants. The presence of microorganisms can be determined, for example, by the presence of ECM in / on a suitable bacterial growth medium. The composition can be directly inoculated into the medium, or other known methods can be used to determine the composition. Examples of the medium include thioglycolate medium and thioglycolate medium.
[0093] The ECM compositions disclosed herein contain low levels of endotoxins or are endotoxin-free. The present invention can be prepared to contain no endotoxins or to contain undetectable levels of endotoxins. The presence of endotoxin in the ECM compositions disclosed herein can be determined, for example, by the Limulus test (Li In the technical field, such as the mulus amebocyte lysate (LAL) test (bacterial endotoxin test), This can be determined by well-known in vitro tests in a particular experiment. In embodiments, the ECM compositions disclosed herein contain 20 endotoxins per preparation. (e.g., one sheet of the ECM disclosed herein contains less than one EU) (including those under EU20).
[0094] 4.2. Methods of Making Extracellular Matrix Compositions In one embodiment, disclosed herein is a method for treating placental extracellular matrix (ECM) In some embodiments, the present invention relates to a method for producing a composition comprising the steps of: The method for producing an ECM composition from a cervix (e.g., a human placenta) includes the steps of: (i) Removal of the amnion, chorion, and umbilical cord from the placenta (e.g., from a placenta obtained from a mother immediately after birth) (ii) removing cells bound to the placental tissue; (iii) exposing the placental tissue to a solution that causes osmotic disruption of the (iv) contacting the placenta with a solution comprising a base. In some embodiments, the method of making an ECM composition from a placenta includes: For example, a method using chorionic membrane of a human placenta includes the following steps in order: (i) extracting a chorionic membrane from the placenta; from placentas obtained from mothers immediately after birth or from preserved placentas. (ii) into a solution that causes osmotic disruption of the cells bound to the chorion; (iii) exposing the chorion to a solution containing a detergent. (iv) contacting the chorion with a solution comprising a base. A method for producing an ECM composition from a placenta, comprising using the chorion of the placenta (e.g., human placenta). The method includes the steps of, in order: (i) extracting a placenta (e.g., from a mother immediately after birth); (ii) obtaining chorionic membrane (from the obtained placenta or from a preserved placenta); (iii) osmotic disruption of the cells bound to the chorion. (iv) exposing the chorion to a solution containing a detergent. and (v) grinding and freeze-drying. A method for producing an ECM composition from a placenta, comprising using the chorion of the placenta (e.g., human placenta). The method includes the steps of, in order: (i) extracting a placenta (e.g., from a mother immediately after birth); (ii) obtaining chorionic membrane (from the obtained placenta or from a preserved placenta); (iii) osmotic disruption of the cells bound to the chorion. (iv) exposing the chorion to a solution containing a first detergent solution, then a second detergent solution. contacting the chorion with a solution containing the detergent solution of 2, said solution comprising the detergent and and a chelating agent, such as EDTA; and (v) lyophilizing. Importantly, the methods of making the ECM compositions disclosed herein include, but are not limited to, the use of bases, detergents, Components such as chelating agents can be added to produce ECM compositions having the special characteristics disclosed herein. Use in an amount that will result in
[0095] The placenta used in the methods of generating ECM disclosed herein is typically a placenta derived from a full-term and may be freshly isolated or previously isolated and frozen. When preparing an ECM composition using a frozen placenta by the method disclosed in The placenta is thawed, e.g., at room temperature, prior to use. For example, the placenta is thawed at ∼22-23°C. The placenta is then thawed for 24 hours or until the placenta is ready to be used.
[0096] In some embodiments, the ECM composition is isolated from the placenta by the methods disclosed herein. Prior to creating the product, the placenta is exsanguinated, i.e., any umbilical cord blood remaining after birth is drained. In some embodiments, the placenta is Before use, it is 70% exsanguined, 80% exsanguined, 90% exsanguined, 95% exsanguined, Or 99% of the time you will be bled out.
[0097] Osmotic disruption of cells bound to placental tissue as performed in the methods disclosed herein Placental tissue (e.g., amnion, chorion, and tissue from the removed umbilical cord) is added to the solution to induce septicemia. or placental tissue derived from the chorion of the placenta), typically results in The blood and blood components are removed as well as the bound cells and cell debris. The authors conclude that any solution that causes osmotic disruption of cells can be used in the methods disclosed herein. It will be understood that any suitable salt may be used. For example, NaCl, potassium chloride (KCl), Ammonium sulfate, monosaccharides, disaccharides (e.g., 20% sucrose), hydrophilic polymers (e.g., , polyethylene glycol), and glycerol, which have the osmotic potential It can be used to disrupt cells by lysis.
[0098] In certain embodiments, placental tissue (e.g., For example, amniotic membrane, chorion, and placental tissue from removed umbilical cord or from the chorion of the placenta. NaCl is used to cause osmotic disruption of the bound cells. At about 0.25M, 0.5M, 0.75M, 1.0M, 1.25M, 1.5M, 1 Solutions containing 0.75M, 2M, 2.25M, or 2.5M NaCl are disclosed herein. To cause osmotic disruption of cells bound to placental tissue used in the method In certain embodiments, about 0.25M to 5M, about 0.5M to 4M, about Solutions containing 0.75M to 3M, or about 1.0M to 2.0M NaCl are disclosed herein. Causes osmotic disruption of cells bound to placental tissue used in the disclosed methods. It is used for this purpose.
[0099] Placental tissue (e.g., amnion, chorion, and tissue from removed umbilical cord or from the chorion of the placenta) The step of contacting the placental tissue (i.e., the placental tissue) with a solution that causes osmotic disruption can be carried out at the discretion of one of skill in the art. In some embodiments, the step can be carried out at any temperature. ℃ to 30 ℃, about 5 ℃ to 25 ℃, about 5 ℃ to 20 ℃, or about 5 ℃ to 15 ℃ In some embodiments, the step is carried out at about 0° C., about 5° C., about 10° C., about 15° C., or about 20° C. ℃, about 20 ℃, about 25 ℃, or about 30 ℃. In another particular embodiment, the step is carried out at room temperature. It is executed in.
[0100] Placental tissue (e.g., amnion, chorion, and tissue from removed umbilical cord or from the chorion of the placenta) The step of contacting the placental tissue (i.e., the placental tissue) with a solution that causes osmotic disruption can be carried out at the discretion of one of skill in the art. In some embodiments, this step may be performed for an appropriate period of time. , about 1-24 hours, about 2-20 hours, about 5-15 hours, about 8-12 hours, or about 2-5 hours In certain embodiments, this step is carried out at room temperature for about 18-26 hours. In another particular embodiment, the step is carried out at 37° C.±5° C. for about 18-26 hours. It will be executed for a while.
[0101] Placental tissue (e.g., amnion, chorion, and tissue from removed umbilical cord or from the chorion of the placenta) The step of contacting the placental tissue with a detergent may be carried out using an ECM composition disclosed herein. This results in the removal of cells and cell debris (e.g., cell membranes) as well as the removal of nucleic acids from the cells. The detergent used in the methods disclosed herein is capable of cleaning cell or organelle membranes (su Any washing agent known to those skilled in the art that can disrupt the bcellular membranes of In some embodiments, the detergent is ionic. For example, In some embodiments, the detergent is sodium deoxycholate, deoxycholate Some examples are benzoyl sulfate, benzoyl ester, and sodium dodecylsulfate. In embodiments, the detergent is zwitterionic. The detergent is non-ionic. For example, in some embodiments, the detergent is TW TWEEN® detergent such as EEN®-20 or TrionX 100 The collagen composition may be a detergent such as TrionX. The cleaning agent is contacted with the object under conditions determined by one of ordinary skill in the art to be suitable for removing the object. obtain.
[0102] In certain embodiments, the cleaning agent used in the methods disclosed herein is a detergent. The sodium deoxycholate is sodium oxycholate or deoxycholic acid. In the methods disclosed herein, cholic acid or deoxycholic acid is used to treat cells, cell debris, and It may be used at any suitable concentration to remove nucleic acids. In an embodiment, sodium deoxycholate or deoxycholic acid is added at a final concentration of, for example, In certain embodiments, the degree of about 1.5%, about 2%, or about 2.5% may be used. Sodium deoxycholate or deoxycholic acid may be used in the methods disclosed herein. It may be used at a final concentration of about 2%.
[0103] In other specific embodiments of the methods disclosed herein, e.g., deoxycholic acid Detergents such as sodium or deoxycholic acid are used, for example, ethylenediaminetetraacetic acid (EDTA). Methods using chelating agents such as diaminetetraacetic acid (EDTA) include: In the first detergent solution, such sodium deoxycholate or deoxycholate For example, the acid may be present at a final concentration of about 0.05% to about 0.1%, about 0.05% to about 0.2%, about 0. 2% to about 0.3%, about 0.3% to about 0.4%, or about 0.4% to about 0.5%, or final concentration of about 0.05%, about 0.06%, about 0.07%, about 0.08%, about 0.09% , about 0.1%, about 0.2%, about 0.3%, about 0.4%, or about 0.5%. In certain such embodiments, sodium deoxycholate or deoxycholate The acid may be used at a final concentration of about 0.067%. Regarding the chelating agent, when the chelating agent is EDTA, such EDTA may be, for example, For example, the final concentration may be about 1 to about 5 mM, about 2 to about 5 mM, about 2 to about 4 mM, about 3 to about 4 mM, or about 5 to about 6 mM. M, about 3 mM to about 5 mM, about 5 to about 10 mM, about 6 to about 10 mM, about 7 to about 9 mM M, or about 8 to about 10 mM, or about 1 mM, 2 mM, 3 mM, 4 mM, 5 mM, 6 The first detergent solution may be used at 5 mM, 7 mM, 8 mM, 9 mM, or 10 mM. In one embodiment, the solution contains sodium deoxycholate or deoxycholic acid. It may contain about 0.067% final concentration and EDTA may contain about 4 mM final concentration.
[0104] In embodiments of the methods disclosed herein, for example, sodium deoxycholate Methods that utilize detergents such as deoxycholic acid in conjunction with chelating agents such as EDTA include In a detergent solution of 2, such sodium deoxycholate or deoxycholic acid For example, the final concentration is about 0.05% to about 0.1%, about 0.05% to about 0.2%, about 0.2 % to about 0.3%, about 0.3% to about 0.4%, or about 0.4% to about 0.5%, or The final concentrations were approximately 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, and It may be used at about 0.1%, about 0.2%, about 0.3%, about 0.4%, or about 0.5%. In certain such embodiments, about 0.2% to about 0.6% sodium deoxycholate Sodium thorium or deoxycholic acid may be used at a final concentration of about 0.39%. Regarding the chelating agent present in the detergent solution, if the chelating agent is EDTA, Such EDTA may be, for example, at a final concentration of about 1 to about 5 mM, about 2 to about 5 mM, about 2 to about 4 mM, about 3 to about 4 mM, about 3 to about 5 mM, about 5 to about 10 mM, about 6 to about 1 0 mM, about 7 to about 9 mM, or about 8 to about 10 mM, or about 1 mM, 2 mM, 3 mM It may be used at M, 4 mM, 5 mM, 6 mM, 7 mM, 8 mM, 9 mM, or 10 mM. In certain embodiments of the first detergent solution, the solution comprises sodium deoxycholate. Alternatively, deoxycholic acid may be contained at a final concentration of about 0.39% and EDTA at a final concentration of about 8 mM. do.
[0105] Placental tissue (e.g., amnion, chorion, and tissue from removed umbilical cord or from the chorion of the placenta) The step of contacting the placental tissue (such as placental tissue) with the detergent can be performed at any temperature as determined by one of skill in the art. In some embodiments, the detergent treatment may be carried out at about 0° C. to 30° C., about 5 C. to 25.degree. C., about 5.degree. C. to 20.degree. C., or about 5.degree. C. to 15.degree. C. In some embodiments, the detergent treatment step is carried out at about 0° C., about 5° C., about 10° C., about 15° C., about 2 The detergent treatment step is carried out at about 0° C., about 25° C., or about 30° C. In certain embodiments, the detergent treatment step is carried out at about 100° C., about 25° C., or about 30° C. In another particular embodiment, the detergent treatment step is performed at room temperature. ℃±5℃.
[0106] The detergent treatment (with or without a chelating agent) may be selected based on the judgment of a person skilled in the art. In some embodiments, the cleaning agent treatment may be carried out for about 1- The method may be performed for 24 hours, overnight, about 24-48 hours, or about 48-72 hours. In another particular embodiment, the cleaning agent treatment step is carried out for about 72 hours. In certain other embodiments, the cleaning agent treatment step is carried out at room temperature for about 72 hours. wherein the detergent treatment step is carried out at 37°C ± 5°C for about 72 hours.
[0107] Placental tissue (e.g., amnion, chorion, and tissue from removed umbilical cord or from the chorion of the placenta) The step of contacting the placental tissue with a base may include contacting the placental tissue with an ECM composition disclosed herein. This results in the removal of some ECM components. For example, denaturing such ECM compositions By this, fibronectin and laminin are removed. Specific examples of groups include biocompatible bases, volatile bases, or groups that are easily and safely removed from the ECM. The base may be, for example, at a concentration of 0.2M to 1.0M. The base may be any organic or inorganic base known to those skilled in the art. The base may be ammonium hydroxide, potassium hydroxide or hydroxide For example, the base is ammonium hydroxide solution, potassium hydroxide solution, or sodium hydroxide solution.
[0108] In certain embodiments, the base treatment step of the methods disclosed herein may be used The base used is sodium hydroxide (NaOH). NaOH is disclosed herein. In the method, the ECM compositions disclosed herein can be used to produce, for example, laminin and fibronectin. Any suitable concentration for removing tin may be used. For example, NaOH may be used as described herein. In the method disclosed in, about 0.1M NaOH, 0.25M NaOH, 0.5MN May be used at concentrations of aOH, 1M NaOH, 1.5M NaOH, or 2M NaOH. In certain embodiments, NaOH is used in the methods disclosed herein at 1M NaOH. It can be used at a concentration of
[0109] The base treatment step can be carried out at any temperature according to the judgment of one of skill in the art. In this embodiment, the base treatment is carried out at a temperature of about 0° C. to 30° C., about 5° C. to 25° C., about 5 ... In some embodiments, the base is reacted at a temperature of about 100° C. to about 20° C., or about 5° C. to about 15° C. The treatment is carried out at about 0°C, about 5°C, about 10°C, about 15°C, about 20°C, about 25°C, or about 30°C. In certain embodiments, the base treatment step is carried out at room temperature. In an embodiment, the base treatment step is carried out at 37°C ± 5°C.
[0110] The base treatment step may be carried out for an appropriate period of time according to the judgment of one of skill in the art. In some embodiments, the base treatment is for about 15 minutes to 30 minutes, 30 minutes to 1 hour, 1- Runs for 2 hours, 2-4 hours, 4-8 hours, 8-12 hours or about 12-24 hours. In one embodiment, the base treatment step is carried out for about 30 minutes. In certain embodiments, the base treatment step is carried out at room temperature for about 30 minutes. In one embodiment, the base treatment step is carried out at 37° C.±5° C. for about 30 minutes.
[0111] In some embodiments, some of the steps of the methods disclosed herein In a further embodiment, the step or all steps are carried out under sterile conditions. The ECM compositions prepared by the methods disclosed herein have the following properties that will be apparent to one of skill in the art: It is further sterilized by the techniques described below.
[0112] In certain embodiments, disclosed herein are methods of making ECM compositions. The method includes (i) separating the amniotic membrane, chorion, and umbilical cord from the placenta (e.g., from a mother immediately after birth); (ii) removing the cytotoxicity of the placenta from a placenta obtained from a zona vitellogenin or from a preserved placenta; and (iii) removing the cytotoxicity of the placenta from a placenta obtained from a zona vitellogenin or from a preserved placenta; and The placental tissue may be bound to a cellular component, such as sodium (NaCl, e.g., 1M NaCl). The remaining placental tissue was homogenized by placing it in a solution that caused osmotic disruption of the cells. (iii) modifying the lysate by, for example, sodium deoxycholate (e.g., 2% deoxycholate); contacting the placental tissue with a solution containing a detergent, such as sodium citrate; (iv) washing the placental tissue with, for example, water; and (v) removing the tissue with, for example, sodium hydroxide (NaO contacting the placental tissue with a solution containing a base, such as 1M NaOH; (vi) Adding an acidic solution, such as hydrochloric acid (HCl), to the solution containing the placental tissue to obtain a neutral pH (vii) a placenta pH of 10.0 or near neutral pH (e.g., pH 6.0-8.0); The tissue is separated from the liquid portion of the solution (e.g., by centrifugation) and the placental tissue is circulated. and recovering the ECM composition, thereby producing the ECM composition. The ECM composition is usually in a paste form (ECM paste) and can be recycled for later use. The ECM preparations described herein may be frozen and stored after harvest, or may be prepared immediately after collection. For example, preparations of ECM sheets, preparations of ECM particles, or preparations of ECM flowable matrices. It can be used in the manufacture of
[0113] In other specific embodiments, disclosed herein is a method of making an ECM composition. The method includes (i) separating the amniotic membrane, chorion, and umbilical cord from the placenta (e.g., from a mother immediately after birth); (ii) removing the placenta from a placenta obtained from a body or from a preserved placenta; (iii) cutting the placental tissue into small pieces, e.g., into 2 x 2 centimeter pieces; Place in 1.5 liters of 1M NaCl solution (e.g., Omni International) and Omni Mixer homogenizer manufactured by Omni International, Kennesaw, GA (iv) homogenizing the placental tissue using a homogenizer; and Place the tissue in a processing container (e.g., a bag) and add 1 M NaCl to make 9.2 liters. and (v) washing the homogenized placental tissue three times with 1 M NaCl. The cleaning step includes the steps of: (a) agitating the processing vessel on a shaker for 10 minutes; (b) allowing the placental tissue to settle in a processing vessel for 10 minutes; and (c) subjecting the tissue to a 6.2 liter removing the supernatant by gravity drainage; (vi) Incubate the washed placental tissue in the remaining 1M NaCl solution at room temperature for 18-26 hours. (vii) washing the placental tissue four times with water as described above. (viii) incubating the washed placental tissue in water at room temperature for 18-26 hours with stirring. (ix) mixing overnight in water and then one final time in the manner described above. Wash with water as described above, then add 6.2 L of 3% sodium deoxycholate and (x) adding sodium deoxycholate to the mixture at a concentration of 2%; and (x) adding placenta tissue. The tissue was mixed on a stirrer in 2% sodium deoxycholate solution at room temperature for ~72 hours. (xi) washing the placental tissue in water five times in the manner described above; i) Finally, water is added, and then the pH of the solution is adjusted to about 10-15 by adding 1M NaOH. (xiii) adjusting the temperature of the placental tissue to 12 to obtain a basic solution; and (xiii) subjecting the placental tissue to a room temperature in the basic solution. (xiv) mixing the mixture on a vortex machine at room temperature for 30 minutes; and (xiv) diluting the mixture with 0.1 N HCl. (xv) adjusting the pH of the solution to about 7.0-7.5; and (xvi) removing the soluble cellulose from the treatment vessel (e.g., removing the supernatant (by centrifugation) and recovering the placental tissue, Thus creating the ECM composition.
[0114] In certain embodiments, disclosed herein are methods of making ECM compositions. The method includes: (i) extracting a cellular component from a placenta (e.g., from a placenta obtained from a mother immediately after birth); (ii) obtaining placental chorion from the preserved placenta; ion) in the placenta, e.g., sodium chloride (NaCl, e.g., 1M NaCl). The placental chorion is homogenized by placing it in a solution that causes osmotic disruption of the cells associated with the chorion. (iii) modifying the lysate by, for example, sodium deoxycholate (e.g., 2% deoxycholate); contacting the placental chorionic tissue with a solution containing a detergent, such as sodium citrate; (iv) washing the placental chorionic tissue with, for example, water; and (v) removing the chorionic villus tissue with, for example, sodium hydroxide. Placental chorionic tissue is placed in a solution containing a base such as sodium hydroxide (NaOH, e.g., 1M NaOH). (vi) contacting an acidic solution, e.g., hydrochloric acid (HCl), with the placental chorionic membrane tissue. Add the tissue to the solution at neutral or near-neutral pH (e.g., pH 6.0-8.0) (vii) separating the placental chorionic tissue from the liquid portion of the solution (e.g., by centrifugation). and recovering said placental chorionic tissue (by cardiotomy), thereby obtaining an E. The ECM composition produced by this method is usually in the form of a paste (EC M paste) which can be frozen and stored after collection for later use or collected Immediately following the preparation of ECM described herein, e.g., preparation of ECM sheets, ECM particles, In some embodiments, the method may be used to prepare a cell culture medium, such as a preparation of a cell, or an ECM fluid matrix. The various steps of the method (e.g., osmotic disintegration, detergent treatment, washing, base treatment) In some embodiments, various steps of the method (e.g. For example, osmotic disintegration, detergent treatment, washing, and base treatment) are performed at 37°C ± 5°C. In some embodiments, the washing step is performed using a volume of 1 / 2 to 2 liters of liquid. - Runs 3 times.
[0115] In other specific embodiments, disclosed herein is a method of making an ECM composition. the method includes (i) extracting from a placenta (e.g., from a placenta obtained from a mother immediately after birth); (ii) obtaining the chorion (from a placenta preserved or preserved in vitro); and (ii) cutting the chorion into strips, e.g. For example, (iii) cutting the placental chorionic tissue into strips of 2 x 2 cm; 100 mL of 1 M NaCl solution (e.g., Omni International) Omni Mixer Homogenizer from International, Kennesaw, GA The placental tissue is homogenized using a homogenizer. (iv) place the homogenized placental chorionic tissue in a processing container (e.g., a bag) and incubate for 1 M. (v) adding NaCl to 9.2 liters; and (v) homogenized placental villi. Washing the membrane three times with 1 M NaCl, the washes comprising: (a) washing the membrane three times with 1 M NaCl; (b) agitating the vessel on an agitator for 10 minutes; (c) placing the placental chorionic tissue in the treatment vessel for 10 minutes; (c) removing 6.2 liters of supernatant by gravity drainage. (vi) removing the washed placental chorionic tissue from the remaining 1M NaCl solution; (vii) mixing the above in a solution on a stirrer at room temperature for 18-26 hours; (viii) washing the placental chorionic tissue four times with water as described above; and (ix) mixing the membrane in water on a stirrer at room temperature for 18-26 hours; After mixing in water overnight, the mixture was washed one final time with water as above, then diluted with 3% Add 6.2 L of sodium deoxycholate to the mixture and add sodium deoxycholate. (x) changing the placental chorionic tissue to 2% sodium deoxycholate; (xi) mixing the placental villi in the thorium solution at room temperature for 72 hours on a stirrer; (xii) washing the membrane five times in water in the manner described above; and (xii) adding water once more. The pH of the solution was adjusted to about 10-12 by adding 1M NaOH to make it basic. (xiii) soaking the placental chorionic tissue in the basic solution at room temperature for about 30 minutes. mixing on a stirrer; and (xiv) adjusting the pH of the solution to about 100 with 0.1 N HCl. (xv) removing the eluate from the processing vessel (e.g., by centrifugation). and (b) removing the supernatant and recovering the placental chorionic tissue, thereby obtaining EC In some embodiments, the wash step comprises preparing the M composition by adding ½ to 2 liters of The procedure is carried out using a volume of liquid.
[0116] In other specific embodiments, disclosed herein is a method of making an ECM composition. The method includes (i) extracting chorionic membrane, e.g., a chorionic plate, from a placenta (e.g., from a mother immediately after birth); (ii) obtaining a placenta from a placenta obtained from a body or from a preserved placenta; and (iii) rubbing and cleaning the chorionic tissue with, for example, sodium chloride (NaCl) 1, e.g., 0.5M NaCl) to disintegrate the cells attached to the chorionic tissue. (iv) placing the cells in a solution that induces sarcoidosis, e.g., deoxycholic acid or deoxycholic acid; Sodium cholate (e.g., 2% deoxycholic acid or sodium deoxycholate) The chorionic tissue is contacted with a solution containing a detergent such as ethanol, and then rinsed with water, for example. and (v) grinding and freeze-drying. The CM composition is usually a paste (ECM paste) and is prepared, for example, by grinding. The ECM composition may be prepared in a variety of shapes or forms. For example, the ECM composition may be prepared in the form of an ECM sheet, ... The preparation may be prepared in a CM particle preparation, or in an ECM fluid matrix, etc. The various steps of the method (e.g., osmotic disintegration, detergent treatment, rinsing) are carried out at room temperature. In some embodiments, various steps of the method (e.g., permeation The steps (pressure collapse, detergent treatment, and rinsing) are performed at 37° C.±5° C. In some embodiments, The flushing step is performed 1-3 times with 1 / 2 to 2 liters of liquid volume. can be.
[0117] In certain embodiments, disclosed herein are methods of making ECM compositions. The method includes the steps of: (i) extracting a human placenta from a mother immediately after full-term birth; Obtain a frozen human placenta or a previously isolated frozen human placenta that has been thawed. (ii) obtaining a frozen sample, e.g., frozen at room temperature for about 24 hours; (iii) washing the placenta in 0.5 M NaCl; and (iv) removing the amniotic membrane, umbilical cord, and decidua parietalis. (iv) removing the chorionic plate from the placenta and retaining the chorionic plate of the placenta; and (v) scrubbing and cleaning the chorionic plate. (v) rinsing the chorion in 0.5M NaCl and in water; vi) Rinse the chorion in 2% deoxycholic acid overnight, followed by several water rinses, e.g. (vii) subjecting the treated product to three, four, five, six, seven or more water rinses; The chorion is then crushed and freeze-dried. The ECM composition is usually in the form of a paste (EC M paste), which is prepared, for example, by grinding and can be prepared in various shapes or forms. For example, the ECM composition may be an ECM sheet, a preparation of ECM particles, or an ECM flowable material. In some embodiments, various steps of the method (e.g., For example, NaCl treatment, deoxycholate treatment, and rinsing) are performed at room temperature. In certain embodiments, various steps of the method (e.g., NaCl treatment, deoxycholic acid In some embodiments, the treatment (acid treatment, rinsing) is carried out at 37° C.±5° C. Rinse steps are performed 1-3 times using 1 / 2 to 2 liter volumes of liquid.
[0118] In other specific embodiments, disclosed herein is a method of making an ECM composition. The method includes (i) extracting chorionic membrane, e.g., a chorionic plate, from a placenta (e.g., from a mother immediately after birth); (ii) obtaining a placenta from a placenta obtained from a body or from a preserved placenta; and (iii) rubbing and cleaning the chorionic tissue with, for example, sodium chloride (NaCl) 1.0M NaCl) to disintegrate the cells attached to the chorionic tissue. (iv) placing the cells in a solution that induces sarcoidosis, e.g., deoxycholic acid or deoxycholic acid; Sodium cholate (e.g., 0.05%-0.2% or 0.3%-0.6% deoxycholic acid) Detergents such as sodium cholic acid or sodium deoxycholate) and EDTA (e.g., 1-5 The chorionic tissue is then contacted with a first detergent solution containing 5 mM EDTA or 5-10 mM EDTA. (v) a step of, for example, deoxycholic acid or sodium deoxycholate (e.g. For example, 0.05%-0.2% or 0.3%-0.6% deoxycholic acid or deoxycholic acid detergents such as sodium phosphate) and EDTA (e.g., 1-5 mM EDTA or 5- The chorionic tissue is contacted with a second detergent solution containing 10 mM EDTA, and then washed with, for example, water. and (vi) freeze-drying the decellularized, freeze-dried whole vitellogenin. and obtaining a whole chorion membrane, which may be, for example, pulverized and dissolved in a solution (e.g., water). or phosphate buffered saline) to prepare decellularized ECM paste. For example, ECM sheets, ECM particle preparations, or ECM flowables may be formed. In some embodiments, the method may be prepared in a variety of shapes or forms, such as a matrix. The various steps of the procedure (e.g., osmotic disruption, detergent / EDTA treatment, rinsing) were performed at room temperature. In some embodiments, various steps of the method (e.g., osmotic disintegration) are performed. The entire procedure (disintegration, detergent / EDTA treatment, and rinsing) is carried out at 37°C ± 5°C. In this embodiment, the rinse step is performed for 1-3 minutes using a volume of 1 / 2 to 2 liters of liquid. It is executed times.
[0119] In certain embodiments, disclosed herein are methods of making ECM compositions. The method includes the steps of: (i) extracting a human placenta from a mother immediately after full-term birth; or previously isolated frozen human placenta that has been thawed, e.g. (ii) obtaining a membrane, an umbilical cord and a parietal membrane, which have been thawed at room temperature for about 24 hours; (iii) removing the decidua from the placenta and retaining the chorionic plate of the placenta; and (iv) rinsing the chorion in 1.0 M NaCl and in water. and (v) a first wash containing 0.067% deoxycholic acid and 4 mM EDTA. Rinse the chorion in the solution overnight, followed by several water rinses, e.g., 3, 4, 5, 6, 7 (vi) 0.39% deoxycholic acid and Rinse the chorion overnight in a second detergent solution containing 8 mM EDTA, followed by a water rinse. (vii) performing several water rinses, e.g., 3, 4, 5, 6, 7 or more; ) freeze-drying the treated chorion. The resulting composition is a decellularized ECM pellet. For example, the composition may be prepared by grinding. In some embodiments, various steps of the method (e.g., NaCl treatment, The deoxycholic acid / EDTA treatment and rinse are carried out at room temperature. In the various steps of the method (e.g., NaCl treatment, deoxycholic acid / ED The TA treatment, rinsing) is carried out at 37° C.±5° C. In some embodiments, Rinse steps are performed 1-3 times using 1 / 2 to 2 liter volumes of liquid.
[0120] In certain embodiments, disclosed herein is a method for producing an ECM sheet. the method comprising: (i) preparing an ECM paste according to the methods disclosed herein; (ii) suspending the ECM paste, e.g., in water, and, e.g., placing the ECM in a mold. placing the suspended ECM solution on a suitable substrate to form a sheet, such as (iii) freezing the ECM; and (iv) freeze-drying the frozen ECM. (v) removing the freeze-dried ECM from the substrate and immersing it in water; and (vi) 2.) drying the ECM using, for example, a vacuum dryer. In particular, the ECM sheets disclosed herein can be formed into, for example, a block, a tube, or other shape. It may be formed into any useful shape.
[0121] In certain embodiments, disclosed herein are methods for producing ECM particles. The method includes: (i) preparing an ECM paste according to the methods disclosed herein; (ii) suspending the ECM paste, for example in water; and (iii) (iv) freezing the ECM; and (v) lyophilizing the frozen ECM. v) grinding the freeze-dried ECM.
[0122] In certain embodiments, the present disclosure provides a method for producing an ECM fluid matrix. A method, comprising: (i) preparing an ECM paste according to the methods disclosed herein; (ii) suspending the ECM paste, for example in water; i) freezing the ECM; and (iv) lyophilizing the frozen ECM. and (v) micronizing the freeze-dried ECM. The M is resuspended in, for example, saline, to generate an ECM fluid matrix.
[0123] Freeze-drying of the ECM compositions produced by the methods disclosed herein is a novel method for the preparation of ECM compositions that are useful in the art. This can be accomplished by any means known in the art, and generally, the ECM composition is substantially until dry, e.g., water is about 30%, 25%, 20%, 5%, 4%, 3%, 2% by weight or progresses until it is less than 1%.
[0124] 4.2.1 Optional Further Processing In some embodiments, the methods disclosed herein include the additional step of: For example, the additional step may include adding a solution capable of causing osmotic disruption of the cells, A process that results in the treatment of an ECM composition that is prepared with a detergent or other agent other than a base. It is a top.
[0125] In certain embodiments, the methods disclosed herein comprise the step of administering BENZONASE® The present invention includes treating an ECM composition prepared by the methods disclosed herein with a cellular endothelial cell culture medium (Cu ... BENZONASE® is a microbial agent that inhibits Serratia marcescens ), a genetically engineered endonuclease that attacks all types of DNA and RNA. Therefore, BENZONASE® is not suitable for use in the manner disclosed herein. The method ensures that the resulting ECM composition is free (or substantially free) of nucleic acids. After treatment with BENZONASE®, the ECM composition The composition may be treated to a high pH and then treated with BENZONASE®. It can be treated to a low pH, which is the appropriate condition for activation.
[0126] In certain embodiments, the methods disclosed herein comprise a method comprising: Therefore, the treatment of the ECM composition prepared with ethylenediaminetetraacetic acid (EDTA) EDTA is a metal chelating agent well known to those of skill in the art and is useful in the methods disclosed herein. Thus, the divalent metal ions may be removed from the ECM compositions disclosed herein. The EDTA can be washed out of the ECM composition using methods known to those of skill in the art.
[0127] In some embodiments, the collagen in the ECM compositions disclosed herein is The crosslinking can be carried out by any crosslinking agent known to those skilled in the art, for example the crosslinking agents mentioned above. In some embodiments, the cross-linking agent is glutaraldehyde. The cross-linking can be carried out by a method known to those skilled in the art, such as cross-linking collagen with glutaraldehyde. In another embodiment, the crosslinking agent is 1,4-butanediol diglycidyl ether. The compounds are tertol or genipin.
[0128] 4.2.2 Storage In some embodiments, the ECM compositions disclosed herein are stored at room temperature. In some embodiments, the E disclosed herein may be used at a temperature of 22-25° C. The CM composition may be stored at low temperatures, for example, refrigerated at a temperature of about 0° C., about 4° C., or about 8° C. In some embodiments, the ECM is not refrigerated. Therefore, the ECM compositions disclosed herein can be stored frozen, e.g., at temperatures below 0° C. The temperature may be, for example, -10°C, -15°C, -20°C, -25°C, -30°C, or -35°C. ,-40℃,-45℃,-50℃,-55℃,-60℃,-65℃,-70℃,-75℃ , -80°C, or -85°C or lower. The freezing and storage of the ECM compositions disclosed herein may be performed at temperatures ranging from 0° C. to −10° C. to -20℃, -20℃ to -30℃, -30℃ to -40℃, -40℃ to -50℃, At temperatures between -50℃ and -60℃, -60℃ and -70℃, or -70℃ and -80℃ It will be held.
[0129] In some embodiments, the ECM compositions disclosed herein are prepared under sterile conditions. and stored under non-oxidative conditions. The ECM composition may be stored at any of the temperatures specified above for 12 months or It will be kept for a period of time.
[0130] 4.2.3.Sterilization In some embodiments, the ECM compositions disclosed herein include those compositions The material is sterilized by techniques known to those of skill in the art for sterilizing objects. In certain embodiments, The ECM compositions disclosed herein can be sterilized by radiation, e.g., gamma irradiation. do.
[0131] In certain embodiments, the ECM compositions disclosed herein can be sterilized using techniques known to those of skill in the art. This is carried out by electron beam irradiation using the method described above. Gorham, D. Byrom (ed.), 1991, Biomaterials, Stockton Press, New York, 55-1 See page 22. At least 99.9% of bacteria or other potential contaminants. Any radiation dose sufficient to kill % is within the scope of the methods disclosed herein. In certain embodiments, terminal sterilization of the ECM compositions disclosed herein is achieved. A dose of at least 18-25 kGy is used to treat
[0132] In some embodiments, the ECM compositions disclosed herein are endotoxin-free. and filtered through a filter that retains the ECM composition. Any size filter known to those skilled in the art for filtering endotoxins, such as 100 kDa. In some embodiments, the filters may be 5 kDa and 100 kDa. For example, the filter may be between about 5 kDa, about 10 kDa, about 15 kDa, a, about 20kDa, about 30kDa, about 40kDa, about 50kDa, about 60kDa, about 70 The filter may be about 80 kDa, about 90 kDa, or about 100 kDa. For example, the ECM compositions disclosed herein, such as cellulose or polyethersulfone, It may be made of any material known to those skilled in the art to be suitable. This can be repeated as many times as desired by one of skill in the art. Endotoxin is detected by standard techniques. and the clearance can be monitored.
[0133] In some embodiments, the ECM compositions disclosed herein are filtered to obtain The present invention produces an ECM composition that is free of or has reduced levels of viral particles. Any filter known to those skilled in the art may be used. For example, a 1000k Da's filters are designed to remove or reduce parvovirus, hepatitis A virus, and HIV. The 750 kDa filter can be used to separate parvovirus and hepatitis A virus. The 500 kDa filter can be used to remove or reduce parvovirus. The filters may be used to remove or reduce the amount of cellulose or Those skilled in the art will recognize that polyethersulfone and other such ECM compositions are compatible with the ECM compositions disclosed herein. The filtration may be of any material known to those skilled in the art. The presence of the virus can be detected by standard techniques and clearance can be performed. can be monitored.
[0134] 4.3.Use The ECM compositions disclosed herein (see 4.1) can be used in numerous ways and for numerous purposes. These may be used for purposes including, but not limited to, patches or tissue plugs or matrix materials, artificial ECM compositions in the manufacture of engineered tissues and organs, including prosthetics and other implantable structures. Use of ECM compositions as tissue scaffolds; Use of ECM compositions in wound repair or coverage Use of ECM compositions as hemostatic devices; e.g., sutures, surgical and cosmetic Orthopedic screws, surgical and orthopedic plates, artificial implants, cosmetic Natural coatings or components for cosmetic implants and supports Use of ECM compositions as devices for use in tissue repair and support, such as Use of ECM compositions in organ or tissue repair or structural support; Use of CM compositions; E as bioengineering platforms Use of CM Compositions; as a Platform for Testing the Effects of Substances on Cells Use of the ECM composition; and use of the ECM composition in cell culture. The composition may be used for cosmetic purposes.
[0135] In some embodiments, the use of the ECM compositions disclosed herein is The ECM composition disclosed herein is administered to a subject. The term "subject" as used herein includes, but is not limited to, primates (e.g., humans). animals, such as cattle, sheep, goats, horses, dogs, cats, rabbits, rats, mice, and other mammals. In certain embodiments, the subject is a human.
[0136] The method of administering the ECM compositions disclosed herein to a subject in vivo includes These include, but are not limited to, oral administration (e.g., buccal or sublingual administration), topical application, This includes aerosol application, transdermal administration, intradermal administration, subcutaneous administration, intramuscular administration, and surgical administration.
[0137] In some embodiments, as part of the uses disclosed herein, The ECM compositions presented may be used in the form of creams, gels, solutions, suspensions, liposomes or other therapeutic and and can be applied in forms known to those skilled in the art as a means for preparation and delivery of cosmetic ingredients. Some examples of suitable formulations for subcutaneous administration include, but are not limited to, Imp. Includes implants, depots, needles, capsules and osmotic pumps. Some examples of suitable preparations include, but are not limited to: pastes, patches, sheets, etc. Suitable preparations for transdermal administration include drops, liquids, syrups, suspensions, aerosols and mists. Some examples of products include, but are not limited to, creams, pastes, patches, spays, and the like. Some examples of suitable delivery mechanisms for subcutaneous administration include, but are not limited to, sprays and gels. Examples of therapeutic agents include, but are not limited to, implants, depots, needles, capsules, and osmotic pumps.
[0138] The ECM compositions disclosed herein are intended to produce a desired physiological or pharmacological outcome. The ECM compositions may be administered to a subject in any form and / or concentration. represents the desired therapeutic endpoint, the desired effective concentration at the site of action or in a body fluid, Information regarding the administration of a substance to a subject can be found in the art. This is known, for example, in L.S. Goodman and A. Gilman, eds. The Pharmacological Basis of Therapeutics, Macmillan Publishing, New York, and Katzung, Basic & Clinical Pharmacology, Appleton & Lang, Norwalk , Conn., (6th Ed. 1995). A practitioner skilled in the field will administer the drug as required by the situation and the substance to be administered. The particular form and concentration, as well as frequency of administration, may be selected depending on the individual.
[0139] 4.3.1. Use in wound care In some embodiments, the ECM compositions disclosed herein are useful in the treatment of wounds. It is used in
[0140] In one embodiment, the ECM composition disclosed herein comprises It is used to treat wounds by placing it directly over the wound site, covering the subject's skin, thus In another embodiment, the ECM compositions disclosed herein are The ECM composition can be used as an implant, for example, subcutaneously, to Those skilled in the art will appreciate that some preparations of ECM compositions meet such specifications. For example, the ECM composition prepared as a sheet may be The ECM sheet can be placed directly over a wound on the skin of a subject to be used for wound treatment. It can be used.
[0141] In some embodiments, the E disclosed herein when used to treat wounds. CM compositions can be prepared to include one or more pharmacologically active agents, including: Non-limiting examples include platelet-derived growth factor, insulin-like growth factor, epidermal growth factor, Transforming growth factor beta, angiogenic factors, antibiotics, antifungals, spermicides, Includes hormones, enzymes, and enzyme inhibitors.
[0142] Wounds that can be treated with the ECM compositions disclosed herein include, but are not limited to, However, epithelial wounds, skin wounds, chronic wounds, acute wounds, external wounds, internal wounds (e.g., ECM The composition is intended to prevent blood leakage from sutures as well as to prevent the body from forming adhesions to the suture material. may be wrapped around the anastomosis site during surgery to prevent the formation of Wounds (e.g., dystrophic epidermolysis bullosa), pressure sores (e.g., decubitus ulcers), partial thickness and partial and full-thickness wounds, venous ulcers, diabetic ulcers, Chronic vascular ulcers, tunneled / undermined wounds, surgical wounds (e.g. For example, donor sites / grafts, post-Mohs surgery, post-laser surgery, podiatric, wound care wound dehiscence), traumatic wounds (e.g., avulsions, lacerations, second degree burns and skin lacerations), and draining wounds Includes.
[0143] In certain embodiments, the ECM compositions disclosed herein include, but are not limited to, First degree burns, second degree burns (partial thickness burns), third degree burns ( Full thickness burns, burn wound infection, excised burn wounds and excised infection of burn wounds that have not been treated with scrub, loss of epithelium from previously grafted or healed burn wounds, and for the treatment of burns and / or burn-related conditions, including impetigo in burn wounds.
[0144] 4.3.2. Dental In some embodiments, the ECM compositions disclosed herein are useful for treating dental disease and Used to treat tusk disorders.
[0145] In one embodiment, the ECM compositions disclosed herein are used in periodontal surgery, periodontal reconstruction, Used in guided tissue regeneration, guided bone regeneration, and / or root coverage to regenerate tissue Such methods include, but are not limited to, matched bilateral periodontal defects. eral periodontol defects, interdental intrabony defects, deep Deep 3-wall intrabony defects, 2-wall intrabony defects y defects and intrabony defects in the periodontal region, including intrabony defects 2 and 3 The present invention includes the use of ECM compositions to promote regeneration of tissue damage.
[0146] In other embodiments, the ECM compositions disclosed herein include, but are not limited to, However, bilateral defects, paired buccal Class II mandibular cartilage molar furcation defects (paired buccal Class II m andibular molar furcation defects, and bilateral mandibular furcation defects Treatment of class II furcation defects, including lar furcation defects It is used in treatment.
[0147] In other embodiments, the ECM compositions disclosed herein include, but are not limited to, is used to treat periodontal disease, including periodontitis and gingivitis. The ECM compositions disclosed herein contain, for example, antibiotics such as chlorhexidine gluconate. The impregnated ECM composition is applied to one or more of the specimens, e.g., greater than or equal to 5 mm. It is used to treat subjects with periodontal disease by inserting it into a periodontal pocket of about It can be used.
[0148] 4.3.3 Oral lesions In some embodiments, the ECM compositions disclosed herein are useful in treating oral lesions. The lesion is not caused by dental or oral surgery. In some embodiments, disclosed herein is a method for treating a patient with an oral lesion. A method of treating a subject, for example, by administering a therapeutically effective amount of any of the compounds disclosed herein. In this context, the term "administration" includes administration of an ECM composition to a subject, such as administration to an oral lesion. In this context, a "therapeutically effective amount" is an amount that reduces or eliminates at least one symptom or aspect of an oral lesion. For example, the ECM composition is administered to repair a lesion. or pain or inflammation resulting from or associated with, for example, an oral lesion. It may be administered as a palliative, to reduce pain, etc.
[0149] In some embodiments, the ECM compositions disclosed herein are used as therapeutic approaches. In another embodiment, the ECM compositions disclosed herein are administered directly to the oral lesion. The composition is administered to, near, or around at least a portion of an oral lesion. For example, placing a sheet of the ECM composition over at least a portion or all of the oral lesion. In some embodiments, the ECM composition can be prepared as a paste. In some embodiments, the ECM composition is administered to the oral lesion as a spray or In some embodiments, the ECM composition is administered to the oral lesion in the form of an aerosol. is administered to the oral lesion in the form of a solution, for example, a mouthwash.
[0150] The oral lesions treated by the methods disclosed herein are characterized by the fact that they cause oral lesions. The condition may be caused by a variety of conditions or treatments known in the art. In some embodiments, the oral lesions treated with the ECM compositions disclosed herein include, for example, Desquamating oral disorders, etc. In other embodiments, the ECM compositions disclosed herein are used to treat or The oral lesions to be treated are, for example, those caused by Behcet's disease or those caused by Behcet's disease. In another embodiment, the lesion is an aphthous ulcer, such as the aphthous ulcers that are part of Prague's disease. Thus, oral lesions treated with the ECM compositions disclosed herein may reduce jaw bone fracture in subjects. Caused by or accompanying death.
[0151] In other embodiments, oral diseases are treated with the ECM compositions disclosed herein. The changes are caused by or associated with graft-versus-host disease. In an embodiment, the oral lesions treated with the ECM compositions disclosed herein are , resulting from or associated with the use of melphalan by subjects with oral lesions.
[0152] In other embodiments, oral diseases are treated with the ECM compositions disclosed herein. The changes are caused by or associated with chemotherapy, which may be, for example, a tumor, blood cancer, or is chemotherapy, such as chemotherapy being administered to a subject to treat other types of cancer. In certain embodiments, the oral lesion is post-chemotherapy oral mucositis or chemotherapy-induced oral mucositis. In another embodiment, the medicament is caused by chemotherapy-induced oral mucositis. The oral lesion is aphthous stomatitis, such as idiopathic aphthous stomatitis. In certain other embodiments, the oral lesion is a canker sore. Mammalian target of rapamycin (mTOR) in subjects with endothelial lesions In certain other embodiments, the present invention relates to a method for treating or preventing rheumatoid arthritis, the method comprising administering to the patient a therapeutically effective amount of rheumatoid arthritis medication ... Oral lesions may be due to or have been caused by the use of 5-fluorouracil by subjects with oral lesions. In certain embodiments, the oral lesions are caused by or associated with chemotherapy. In this case, the oral lesions are caused by or associated with, for example, a chemotherapeutic agent, and the chemotherapeutic agent is, for example, For example, alkylating agents (e.g., busulfan, cisplatin, carboplatin, cyclophosphamide, fosfamide, dacarbazine, ifosfamide, mechlorethamine or melphalan); Antibody antagonists (e.g., 5-fluorouracil, methotrexate, gemcitabine, cytopenic acid anticancer antibiotics (e.g., bleomycin, dacridine, tinomycin, daunorubicin, doxorubicin or idarubicin) or mitotic inhibitors ( For example, paclitaxel, docetaxel, etoposide, vinblastine, vincristine or vinorelbine. is undergoing or has undergone a course of treatment, such as chemotherapy, The progression of the oral lesions in In this context, "early termination" means, in part or in part, Overall, as a result of the oral lesions, a course of treatment was prescribed for the subject. This means that the command will finish before
[0153] In other embodiments, oral diseases are treated with the ECM compositions disclosed herein. The alterations are caused by or associated with administration of the antibody to a subject in need of treatment. In an embodiment, the antibody is an anti-CD20 antibody. In one embodiment, the antibody is rituximab (e.g., RITUXA N®), ofatumumab (e.g., ARZERRA® ), veltuzumab or ocrelizumab. In an embodiment, the antibody is an anti-tumor necrosis factor antibody. In a more particular embodiment, the antibody is adalimumab ) (e.g., HUMIRA®), etanercept (e.g., E NBREL®), infliximab (e.g., REMICAD E®), certolizumab pegol (CIMZIA®), trademark), natalizumab (e.g., TYSABRI®), or is golimumab (e.g., SIMPONI®). In one embodiment, if the subject is undergoing or has undergone antibody therapy, the subject The progression of the oral lesions in the subjects was associated with premature termination of the antibody treatment. In this context, "premature termination" refers to the partial or total termination of said oral lesions. As a result, antibody treatment may be terminated earlier than expected for the subject. do.
[0154] 4.3.4.Void filling In some embodiments, the ECM compositions disclosed herein are administered intracellularly to a subject. It is used to seal, fill, and / or otherwise treat voids. The term "void" as used herein means any undesired cavity in a subject. The unwanted cavities may be caused by, for example, aging, disease, surgery, For example, the voids may be caused by tumors or other The present invention may be formed after the surgical removal of a mass of E from a subject. Non-limiting examples of voids that may be filled with the CM composition include fissures, fistulas, and ), diverticula, aneurysms, cysts, lesions, or other tissues in various organs or tissues of the subject's body. This includes any undesirable voids in the
[0155] In some embodiments, the ECM compositions disclosed herein are administered to tissues, organs or other body structures (e.g., blood vessels) or junctions between adjacent tissues, organs or structures; To fill, seal and / or treat all or part of a fissure, crack or fistula in For example, they may be used to prevent bodily fluids, such as blood, urine, or other bodily fluids, from leaking out. The ECM compositions disclosed herein can be injected, implanted, inserted, into a fistula between internal organs or into an opening from an internal organ to the outside of the subject's body The ECM compositions disclosed herein can be applied to the ing or orifice. filling voids or other defects formed by these pathological conditions, in addition to fibroblast infiltration, It can be used to promote healing and ingrowth of tissue.
[0156] In one embodiment, disclosed herein is a schizophrenia that fills a fistula in a subject. and / or other treatment methods, said methods comprising the steps of: Injecting or otherwise administering the ECM composition to the subject. is injected through the needle into one of the fistular orifices and It may be administered to a subject by filling most or all of the branches of the orifice. Strings or rods of the ECM composition are inserted into the fistula lesion through the orifice. Alternatively, collagen may be introduced into the subject via a catheter. The disclosed ECM compositions can be used to treat, for example, anal, arteriovenous, bladder, carotid-cavernous carotid-cavernous, external, gastric, intestinal, parietal, salivary Various types of fistulas, such as rectal, vaginal, and anorectal fistulas or combinations thereof, are filled. The tissue may be sealed and / or have other treatments applied.
[0157] In one embodiment, disclosed herein is a method for filling a diverticulum in a subject. and / or other treatment methods, said methods comprising the steps of: The method includes injecting or otherwise administering the ECM composition to a subject. A physiological structure that does not have a bladder, e.g. a sac-like or pouch-like structure from a tubular or pouch-like organ such as the intestine, bladder, etc. The openings are filled or augmented with the ECM compositions disclosed herein. gmented).
[0158] In other embodiments, what is disclosed herein is a method for filling a cyst in a subject. and / or administering other treatments, said methods comprising administering to a subject an E1-containing In some embodiments, the CM composition is administered to the subject by injection or other methods. In the present study, the cyst is a pseudocyst, i.e., it contains an accumulation of fluid, but is not lined with epithelium or other membranes. Does not contain a molded membranous lining. Filled, sealed and / or Additional non-limiting examples of cysts that may be amenable to other treatments include sebaceous cysts. , dermoid cyst, bone cyst or serous cysts or any of these Includes combinations.
[0159] In other embodiments, the ECM compositions disclosed herein are administered by injection or other means. and removing unwanted or undesirable tumors, fluids, cells, or tissues from the subject surgically or Any voids formed as a result of chemical or biological removal shall be completely or partially filled. The ECM composition can be locally injected or otherwise administered to the site of the void. This can be used to augment the remaining or surrounding tissue, facilitating the healing process and minimizing the risk of infection. This enhancement can be seen, for example, in tumor-associated tissue, bone tissue, or cartilage tissue following breast cancer surgery. It is particularly useful in the area of voids that form after tumor resection, such as after surgery to remove tissue.
[0160] 4.3.5 Tissue bulking In other embodiments, the ECM compositions disclosed herein are used to enhance tissue bulking. As used herein, the term "tissue bulking" means , external motion or soft tissue that is not the skin of a subject (e.g., human) in its natural state The tissues encompassed in this specification are not intended to be limiting. However, it includes muscle tissue, connective tissue, fat, and nerve tissue. Such tissues are parts or can be body parts, including but not limited to the sphincter, bladder sphincter, and urethra.
[0161] 4.3.6 Urinary incontinence In other embodiments, the ECM compositions disclosed herein are used to treat urinary incontinence (stress urinary incontinence The drug may be used to treat stress urinary incontinence, which may be caused by, for example, coughing. Sudden leakage of urine that occurs with actions that increase intra-abdominal pressure, such as sneezing, laughing, or exercise According to such embodiments, the ECM compositions disclosed herein can be, for example, Injected into a subject to augment the subject's sphincter muscle tissue, thereby improving or restoring sphincter function within the subject. The ECM compositions may be injected or otherwise administered periurethrally to manage urinary incontinence and and / or increase the tissue bulk around the urethra for treatment. Improvement of stress incontinence may be achieved by increasing the tissue bulk. This can be achieved by increasing the resistance to urine outflow. .
[0162] In some embodiments, the ECM composition is injected or otherwise administered around the urethra of a subject. For example, the ECM composition may be administered to the urethra, a hole in the urethra through which urine leaks out. The urethra closes or thickens the wall of the urethra, creating a tight seal when urine is being held.
[0163] In another embodiment, the ECM composition is injected or otherwise administered into the urethra of a subject. The injection is given just outside the urethra muscle at the exit of the bladder. The injection of the bulking material penetrates the skin. This can be done through the vagina, through the urethra, or in women through the vagina.
[0164] 4.3.7 Vesicoureteral reflux disease In other embodiments, the ECM compositions disclosed herein are administered retrograde from the bladder to the kidney. Vesicoureteral Reflux (VUR) is a condition characterized by a flow of urine that or urinary reflux. The ECM compositions disclosed herein can be injected or otherwise administered to a subject in need thereof. may be administered, the wall of the ureter of the subject may be strengthened, and the symptoms of VUR may be reduced or eliminated. The composition may be administered, for example, by injection (e.g., subtrigonal injection) under endoscopic guidance. The catheter may be inserted into the detrusor muscle backing below the ureteral orifice using a catheter injection or other method known to those skilled in the art. Administration can be accomplished using a variety of methods known in the art.
[0165] 4.3.8 Gastroesophageal reflux disease In other embodiments, the ECM compositions disclosed herein are administered to the lower esophageal sphincter (lower esophageal sphincter). The esophageal sphincter (LES) -- the muscular valve where the esophagus joins the stomach -- does not close properly. This occurs frequently when the esophagus becomes loose or weakened, allowing stomach contents to leak into the esophagus. Gastroesophageal Reflux Disease (GERD), a disorder in which the esophagus leaks back or flows backwards According to such embodiments, the present invention may be used to treat gastroesophageal reflux disease (GERD). The ECM compositions presented can be injected or otherwise administered to a subject in need thereof, The subject's LES may be enhanced and the symptoms of GERD may be reduced or eliminated. In some embodiments, the ECM composition is administered under endoscopic guidance to the esophageal wall at the gastroesophageal junction. The effect of bulking, which aims to prevent backflow, is determined by the amount of retained material and the resulting This is due to the combination of tissue reactions that occur. The ECM composition may be standard or thick (e.g., It can be injected through a large gauge needle.
[0166] 4.3.9 Vocal Cords and Larynx In other embodiments, the ECM compositions disclosed herein are administered to one or both vocal folds (e.g., A disease or disorder that affects the vocal cords (folds) and / or the larynx (voice box) The devices may be used in the management or treatment of larynx and voice disorders, such as neurological disorders, or other abnormal conditions. Non-limiting examples of such diseases, disorders or other abnormal conditions of the glottis include glottal insufficiency (GLOT). ottic incompetence, unilateral vocal cord paralysis, bilateral Bilateral vocal cord paralysis, paralytic dysphonia ), nonparalytic dysphonia, spasmodic dysphonia a) or a combination thereof. The M composition may be affected by, for example, aging (presbylaryngis) ), and / or scarring of the vocal cords (e.g., from previous surgery or radiation therapy), e.g. For example, incomplete paralysis of the vocal cords ("paresis"), which are generally weak vocal cords. Used in the management or treatment of a disease, disorder or other abnormal condition that results in improper closure of the vocal cords, such as obtain.
[0167] The ECM compositions disclosed herein are intended to provide a method for the removal of tissue from a subject that is missing a volume that it once possessed. Lack of mobility (e.g. vocal fold bowing or atrophy) or mobility (e.g. vocal fold atrophy) It can be used to provide support or bulk to the vocal cords. In some embodiments, the vocal cords and / or other laryngeal soft tissues may be treated, alone or in combination with other treatments. or in combination with medication, may be enhanced by the ECM compositions disclosed herein. In one embodiment, the ECM compositions disclosed herein are provided in a single (or bilateral) By strengthening the cord or adding volume, the vocal cord can come into contact with the other vocal cord.
[0168] Any of a number of procedures well known to those of skill in the art can be used to prepare the ECM compositions disclosed herein. to the vocal cords or larynx of a subject. A curved needle is used to inject the ECM compositions disclosed herein through the mouth of the subject. In another embodiment, the ECM compositions disclosed herein are administered to the skin and A needle (e.g., a higher gauge, shorter needle) is used to administer the drug directly through the Adam's apple. That's fine.
[0169] In some embodiments, the ECM compositions disclosed herein are useful in the management of vocal cord paralysis. In one embodiment, the ECM disclosed herein may be used in a therapeutic or therapeutic setting. The composition is administered to a subject by injection or other means to induce cell proliferation. Manage or treat lateral or bilateral vocal cord paralysis or related symptoms in subjects In one embodiment, the method is used to improve vocal cord closure in a subject. The CM composition augments or adds volume to one (or both) paralyzed vocal cords, The vocal cords can be in contact with other vocal cords. Injection of the ECM composition into the subject The drug may be administered directly through the mouth or through the skin and Adam's apple.
[0170] In some embodiments, the ECM compositions disclosed herein provide a variety of vocal-related It can be used to treat dysphonia, which is a significant impairment or difficulty speaking. .
[0171] 4.3.10 Glottal insufficiency In some embodiments, the ECM compositions disclosed herein are useful for treating glottal dysfunction. Percutaneous laryngeal collagen augmentation may be used in the management or treatment of The vocal cord injection method involves injecting an ECM composition into a subject's vocal cords using methods known to those of skill in the art. In some cases, subjects may experience dysphonia and / or laryngeal Glottal insufficiency, increased muscle stiffness, and decreased motor function of the thyroarytenoid muscles affecting speech production In another embodiment, the dysphonia is due to Parkinson's disease. In one embodiment, the ECM composition is administered by injection or other means to the vocal cords of a subject. The present invention is used to manage or treat glottal dysfunction in a subject in need thereof by administering The injection may strengthen the vocal cords and improve glottal closure, resulting in improved glottal function in the subject. The deficiency is reduced or eliminated.
[0172] 4.3.11 Bioengineering In other embodiments, the ECM compositions disclosed herein are used to enhance the bioavailability of tissues or organs. It can be used in bioengineering, for example as a tissue replacement agent. Bioengineered tissue that can be produced using the ECM compositions disclosed herein. Examples of bioengineered components include, but are not limited to, bone. , tooth structure, joints, cartilage, skeletal muscle, smooth muscle, cardiac muscle, tendons, menisci, ligaments, blood vessels, stents ( stents, heart valves, corneas, eardrums, nerve guides, tissue or organ patches or Sealants, fillers for missing tissue, sheets for cosmetic repair, skin (skin and The soft tissue in the throat, such as the trachea, epiglottis, and vocal cords, is also called the endothelial cell sheet. Soft tissue structures, such as nasal cartilage, tarsal plate, tracheal ring, thyroid cartilage, arytenoid cartilage, etc. Other cartilage structures, connective tissue, vascular grafts, and their components, and sheets for repair or replacement of organs such as the liver, kidney, pancreas, etc.
[0173] 4.3.12 Beauty applications The ECM compositions disclosed herein are further useful in cosmetic applications. In such cosmetic applications, the ECM compositions disclosed herein may be administered intradermally or intradermally to a subject. Lines, creases and other wrinkles on the skin e) is used to fill in and restore a smoother, younger looking appearance. do.
[0174] In some embodiments, the ECM compositions disclosed herein are used to treat skin atrophy in a subject. It can be used for skin augmentation. In one embodiment, the method of augmenting skin in a subject comprises administering an ECM composition disclosed herein to a subject. This includes administering, by injection or other means, to the face or body area of a subject in need of such treatment. The subject's facial or body area is enhanced as compared to that area prior to administration of collagen. The term "skin augmentation" as used herein refers to the augmentation of skin in a natural state. Any change in the (e.g. human) skin or related areas due to an external action or influence Non-limiting areas of the skin that can be altered by skin augmentation include the epidermis, dermis, Subcutaneous layer, fat, arrector pill muscle, hair shaft, sweat pore, sebaceous gland, or a combination of these Includes combinations.
[0175] An example of a cosmetic application of the ECM compositions disclosed herein is the application of ECM compositions to treat wrinkled or pitted areas of the face. In addition, to enhance an area, add fullness to an area of a subject's face or body or to enhance the appearance of that area. Use of ECM compositions to increase the fullness of areas, including but not limited to wrinkles ( wrinkles, depressions, or other creases (e.g., frown lines, forehead Worry lines, crow's feet, marionette lines stretch marks, internal or external scars (e.g., from injuries, wounds, ECM compositions for treating skin defects, including scars from accidents, bites, or surgery Use of ingredients that result in dark circles around the eyes and "hollow" eyes Use of ECM compositions to correct visible vessels; lower eyelid formation Correction of under-eye area after aggressive removal of under-eye fat pads by blepharoplasty, cheek For correction of the lower cheeks after aggressive fat extraction, as well as rhinoplasty, skin grafts, or liposuction Consequences of other surgically induced irregularities such as indentations Use of ECM compositions to correct or augment cosmetic procedures, including correction of scars on the face or body ( Use of the ECM composition to correct scars (e.g., wounds, chicken pox, or acne scars); and The present invention includes the use of ECM compositions for facial remodeling.
[0176] 5. Kit In other aspects, the present disclosure provides a method for the preparation of a medicament for the treatment of a disease comprising administering to the patient an ECM composition as disclosed herein. It is a kit.
[0177] In one embodiment, disclosed herein is an ECM disclosed herein. The kit includes a composition, and the ECM composition is prepared as a sheet. The ECM sheets are provided in a sterile form and packaged in a pouch. The sheets of ECM provided in such kits may be of various sizes (e.g. , 5×5 cm or 9×9 cm) and thickness (e.g., 1.5-2.5 mm), depending on the practitioner. It is ready for use, for example as a wound dressing.
[0178] In other embodiments, disclosed herein are ECM compositions disclosed herein. The kit may include the ECM composition, which may be formulated as a flowable matrix. In the kit, the ECM composition is provided in a sterile form and in a fine powder form in a glass vial. Such vials contain various amounts of finely powdered ECM. The flowable matrix may contain, for example, 200 mg of finely powdered ECM. The kit containing the ECM composition to be prepared as a suspension of finely powdered ECM is Components suitable for use in the procedure, such as a suspension solution (e.g., saline solution) and a needle and soft tissue. and a syringe including a soft applicator.
[0179] In another embodiment, a kit comprising the ECM composition disclosed herein, The ECM composition is prepared as particles. In such kits, the ECM composition is sterile and It is provided in a crushed form and packaged as crushed ECM in a glass vial. Such vials may contain various amounts of ground ECM, e.g., 100 mg or 20 mg. 0 mg of ground ECM.
[0180] The kits disclosed herein include, but are not limited to, those for use with the ECM compositions provided in the kits. In some embodiments, the label or indicia may include instructions for use. The kit is useful for carrying out a method for which the ECM composition is effective. For example, the component may include an ECM composition in the kit. A means for administering something, such as one or more spray bottles, tweezers, spatula, etc. tubules (for applying pastes or particles), cannulas, catheters, etc. It is.
[0181] 6. Working Example 6.1. Example 1: Method for Producing Placental ECM This example discloses a method for producing placental ECM, which is first prepared as a paste. do.
[0182] Method 1: A previously isolated, frozen human placenta was obtained and thawed at room temperature for ~24 hours. After the placenta was thawed, the amnion, chorion, and umbilical cord were removed from the placenta and discarded. The placenta was then cut into 2 x 2 cm strips for processing.
[0183] The placental tissue was placed in a container containing 1.5 liters of 1M NaCl solution and incubated for 24 hours. Omni Mixer Hall, manufactured by Omni International, Kennesaw, GA The homogenized fetus was then homogenized using an Omni Mixer Homogenizer. The tissue was placed in a processing bag, which was then filled with 1M NaCl. The homogenized placental tissue was filled in 1M NaCl solution to a total volume of 9.2 L. (i) The process bag was washed three times with 0.5 mL of water on an orbital shaker. (ii) the placental tissue was allowed to settle in the process bag for 10 minutes; (iii) 6.2 liters of supernatant was removed from the process bag by gravity drainage. This step removes blood and debris from the mixture.
[0184] After the third washing step, the washed placental tissue was incubated at room temperature for ~18-26 h orbital. The mixture was mixed in 1M NaCl solution (total 3 liters of mixture) on a tub shaker. The placental tissue was then washed four times with sterile water, similar to the NaCl wash described above. After washing in 0.5% CO, the placental tissue was incubated for ~18-26 h on an orbital shaker at room temperature in 0.5% water. After mixing in water for ~18-26 hours, The placental tissue was washed one final time with water as described above, and then washed with 6.2 L of 3% Sodium deoxycholate is added to the mixture, and the deoxycholate in the mixture is The final sodium concentration was 2%.
[0185] The placental tissue was incubated in 2% deoxycortisone on an orbital shaker at room temperature for ~72 hours. After mixing for ~72 hours, the placental tissue was then mixed in the sodium phosphate solution as described above. The plates were washed five times with sterile water in the same manner. After the final addition of water, 1M NaOH was added dropwise. The pH of the solution was adjusted to about 10-12 by the addition of 10 sulphate, making the solution basic. The placental tissue was mixed in the basic solution for ∼30 min at room temperature on an orbital shaker. After mixing for .about.30 min, the pH of the solution was adjusted to approximately 7.0 by dropwise addition of 0.1 N HCl. Adjusted to -7.5.
[0186] The supernatant was removed from the process bag and the remaining placental tissue was collected and centrifuged. After centrifugation, the supernatant was removed and the collected placental tissue was sterilized as a final washing step. It was resuspended in sterile water and centrifuged again, after which the supernatant was discarded. The resulting composition is a placental ECM composition containing collagen and elastin, and is It was in the form of a strike.
[0187] Method 2: Once processing has commenced, the frozen human placenta is thawed at 2-8°C and kept in a biosafety kit. The animals are then transferred to a biological safety cabinet (BSC) and treated in the same manner as in Method 1. The placenta was removed from the storage container and placed on a sterile, disposable tray. The placenta was cleaned to remove excess blood and blood clots and minced into small pieces. The extracted placental material was suspended in sterile water and homogenized using a mechanical homogenizer. The resulting microscopic tissue particles have an increased surface area and are similar to placenta tissue. Allows for more efficient separation and removal of cells and cell debris from the ECM. Placental tissue was placed in a sterile process bag containing sterile 1M sodium chloride solution. The tissue was then orbited several times with sterile 1M sodium chloride (NaCl). The tissue was washed by agitation on a tub shaker; the NaCl solution precipitated the placental tissue, The solution was then drained and replaced by adding additional sterile 1M NaCl solution. Placental tissue was incubated in a sterile 1M NaCl solution for 18-24 hours under agitation. The plates were then held in a cool, dark place for 24 hours, followed by repeated washing with sterile water. All processing steps were carried out at room temperature. Exposing placental tissue to high concentrations of sodium chloride, followed by water, reduced the toxicity of the tissue. This "osmotic shock" is caused by the blood, blood This helps to clear out fluid, cells and cell debris. The placenta tissue is then Before being washed with detergent, it is subjected to a second "osmotic shock".
[0188] The rinsed placental tissue was then resuspended in sterile 0.1-0.3% sodium deoxycholate ( DOC) solution and 4-8 mM ethylenediaminetetraacetic acid (EDTA) solution. In a bio-processing bag, the mixture is stirred at room temperature for 48-72 hours. After subsequent rinsing with sterile water, the tissue was then rinsed with DOC / EDTA for a second time. The tissue was rinsed to remove DOC and EDTA for 18-24 hours. Sterile water was used to make the solution.
[0189] Once the water wash is complete, the supernatant is removed from the bioprocess bag and diluted with 2 mM salt. Magnesium chloride solution and 10 U / mL BENZONASE® at pH 8-9 The mixture was replaced and mixed at room temperature for 18-24 hours. It is an endonuclease that degrades all types of nucleic acids (RNA and DNA); The unwanted polynucleotide fragments are washed away by a series of rinses of the placental tissue.
[0190] After rinsing of the placental tissue to remove residual nucleic acids, the material was subjected to In the first step, the placental tissue was treated with low and high pH. is brought to a pH of 3.3 or less in the presence of sterile 0.67M NaCl solution; The mixture was stirred on an orbital shaker at 22±1° C. for 24 hours. The pH of the solution is adjusted to ≧13 using sodium hydroxide (NaOH) and is kept at 22±1 The mixture was mixed in the bioprocess bag on an orbital shaker at 4 °C for a minimum of 4 hours. At the end of the NaOH exposure, the pH of the solution was in the range of 5.5-9.0. Adjusted.
[0191] After the acid and base treatment, the tissue was incubated with 1M NaCl. The cells were then immersed in water and mixed on an orbital shaker for 48-72 hours. The placental ECM was then washed with sterile water for 18-24 hours to remove debris and residual contaminants. The suspension was centrifuged to produce an ECM paste. The paste was stored in a -20°C freezer until the product was prepared and sterilized.
[0192] Preparation as sheets: To generate ECM sheets, ECM paste is incubated at 2 °C for 2 h. Thaw at 2°C for 24-48 hours and store in sterile phosphate buffered saline in a biological safety cabinet. The tissue was homogenized to prepare a homogenous ECM suspension, and the suspension was resuspended in buffer. The suspension was dispensed into sterile plastic molds and frozen. Frozen ECM moulds The ECM wafers were dehydrated using freeze-drying. The cells were then rehydrated in sterile water and then dried at room temperature for 18-36 hours in a vacuum-assisted dryer. The sheets were then packed in a double pouch and sealed with a medical grade sealer. It was sealed, labeled and sterilized using gamma radiation.
[0193] Preparation as particles: To generate ECM particles, the ECM paste is resuspended in sterile water. The mixture was then transferred to a mold and shipped to Thermo Scientific, Marietta, Ontario. The samples were frozen using a Controlled Rate Freezer manufactured by H) A freeze-dryer manufactured by LabConco (Kansas City, MO) was used. The ECM was freeze-dried for 48 hours. The freeze-dried ECM was purchased from Fluid Energy. The ECM particles were generated using a jet mill manufactured by Sigma Chemical Co., Ltd., Telford, PA. The ground ECM powder can be filled and sealed into amber glass vials.
[0194] Preparation as a flowable matrix: ECM flowable matrices can be prepared using ECM particles. Typically, ECM flowable matrices are prepared by lyophilizing and pulverizing ECM (ECM particles) in a sterile, It may be prepared by suspending in water or saline.
[0195] 6.2. Example 2: Determination of Collagen Content of ECM Compositions This example describes the analysis of collagen content of ECM compositions.
[0196] EC prepared in the form of particles, sheets, or flowable matrices as described in Example 1 The M composition was assayed for total collagen content using a colorimetric hydroxyproline assay. Collagen has a very high proline content. Collagen is a unique protein in that it is converted into hydroxyproline. As such, it can be obtained from collagen hydrolyzed in hot hydrochloric acid. Hydroxyproline quantification, which can be used to quantify collagen, has been used as a surrogate for collagen quantification. obtain.
[0197] The ECM sample was hydrolyzed with 6N HCl at 110°C. Then, Chloramine-T (N-chloro-4-methylbenzenesulfonamide) Hydroxyproline was oxidized using N-chloro 4-methylbenzenesulfonamide. Pyrrole-2-carboxylic acid (pyrrole) The color is due to 4-Dimethylaminobenzaldehyde (DM The hydroxyproline content was measured by measuring the absorbance at 550 nm. The absorbance of the samples was determined by ELISA using known amounts of hydroxyproline. The concentrations were interpolated against a hydroxyproline standard curve.
[0198] The ECM composition contains a total collagen content ranging from 31% to 53% by weight of the ECM composition. Fourteen of the 16 samples were determined to contain approximately 100% ECM composition by weight (Table 1). The total collagen content was in the range of 34% to 43%. Twelve of the 16 samples were also Total collagen by weight of the CM compositions ranged from 37% to 42%. The comparator matrix product, porcine urinary bladder matrix, ix) MATRISTEM® Wound Matrix sheets or MATRISTEM MICROMATRIX® particulates and Fetal bovine dermis matrix (PRIMATRIX™ Dermis The Dermal Repair Matrix (DRM) was 67%, 67%, and 69% of the total mass, respectively. It was found to contain largen.
[0199] [Table 1]
[0200] 6.3. Example 3: Determination of Elastin Content of ECM Compositions This example describes the analysis of the elastin content of ECM compositions.
[0201] The ECM composition prepared as particles or sheets as described in Example 1 can be used as a bio Fastin Elastin Quantitation Kit (BioColor, Ltd. (UK)) The elastin content was analyzed using the elastin assay kit. To stain the alpha-elastin extracted and solubilized from the sample. , 5, 10, 15, 20-Tetraphenyl-21, 23-porphine tetrasulfonate (5, 10, 15, 20-tetraphenyl-21, 23-porphine tetra-sulfonate (TPPS) is used as the dye. Lastin was extracted from ECM composition samples in 0.25 M oxalic acid at 100°C. Rustin is a compound made from trichloroacetic acid and hydrochloric acid (TCA / HCl). The elastin was precipitated with TPPS and then stained with TPPS. The levels of released TPPS were quantified by spectrophotometry. Elastin levels in ECM composition samples were interpolated against an elastin standard curve. This was determined by:
[0202] The ECM composition has an elastin content ranging from 13% to 29% by weight of the ECM composition. In 14 of the 16 samples, elastin was determined to be 16% by weight of the ECM composition (Table 2). % to 24%, and 13 of the 16 samples contained elastin by weight of the ECM composition. The range of ECM composition was 17% to 24%, with 10 of the 16 samples containing ellagic acid by weight of the ECM composition. The percentage of sucrose in the comparative sample was in the range of 20% to 24%. Porcine Bladder Matrix (MATRISTEM®) Wound Matrix Sheet or Matristem Micromatrix (registered The PLA-1000001 (PLA-1000001) particles were found to contain 4% elastin. In the matrix (PRIMATRIX™ dermal repair matrix), elastin was not detected. I couldn't.
[0203] In Tables 2 and 3, Sample 8 shows the same ECM composition as Sample 8 in Table 1. However, the types of ECM compositions analyzed differ (i.e., the form of a flowable matrix in Table 1). In Tables 2 and 3, ECM compositions in the form of particles were analyzed. was done).
[0204] [Table 2]
[0205] 6.4. Example 4: Determination of Fibronectin Content of ECM Compositions This example describes the analysis of the fibronectin content of ECM compositions.
[0206] The ECM composition prepared as particles or sheets as described in Example 1 was Takara Fibronectin EIA Kit (TaKaRa Fi The fibronectin content was analyzed using a fibronectin EIA kit. Based on the sandwich ELISA method, Two mouse monoclonal anti-human fibronectin antibodies 2) to detect fibronectin. A special extraction method for fibronectin was developed using urea buffer of M. Ta.
[0207] 15 mg of ECM composition was dissolved in 3 mL of extraction buffer (2 M urea, 0.05 M PO4, 2 The cells were mixed with 10 mM PMSF, pH 7.1, and mixed on a stir plate for 4 hours. The samples were then centrifuged at 10,000Xg. The supernatant was stored at -20 The samples were stored at 4 °C or used immediately. Analysis of the 16 ECM composition samples was performed according to the manufacturer's instructions. A standard curve of fibronectin concentration was constructed using commercially available lyophilized fibronectin. The fibronectin concentrations of the samples were then interpolated from the curve.
[0208] The fibronectin content of the ECM composition was low, averaging 19 per mg of ECM composition. Contains 7 ng of fibronectin (0.0197% by weight of the ECM composition), ranging from 21.3 ng / mg to 361 The range of 0.3ng / mg was 0.1ng / mg. Wound matrix sheet or MATRISTEM Micromatrix MICROMATRIX® particles) and fetal bovine dermis matrix (Primatr PRIMATRIX™ Dermal Repair Matrix was tested, but in this assay The amount of fibronectin was not determined. This is because the antigen used in the assay This may be because the body did not cross-react with bovine or porcine derived substrates.
[0209] [Table 3]
[0210] 6.5. Example 5: Determining the Laminin Composition of ECM Compositions 16 ECM prepared as particles or sheets as described in Example 1 The composition was a Takara Fibronectin EIA (Mountain View, CA). The cells were analyzed for laminin content using a kit according to the manufacturer's instructions. The kit is based on the sandwich ELISA method and uses two steps to measure the expression of the IgG from two mice. A monoclonal anti-human fibronectin antibody is used to detect laminin. A special extraction method for laminin was developed using urea buffer of 1000 M. The standard curve for laminin concentration was The lines were made using commercially available lyophilized laminin, and the laminin concentration of the samples was was interpolated from the curve.
[0211] Results: Laminin was not detected in any of the 16 ECM samples. Either porcine bladder matrices (sheets or particles) or fetal bovine dermis matrices were analyzed for However, no laminin was detected.
[0212] 6.6. Example 6: Biocompatibility of ECM Compositions Prepared as sheets, particles or flowable matrices as described in Example 1. The ECM composition was determined for subjects aged 4.7-6.3 months and weighing 2.4-2.9 months at the start of the study. Biocompatibility was tested in kg albino New Zealand White rabbits. As a control, the ECM sheet was placed on a MATRISTEM® wound bed. The ECM particles were compared to the matrix (porcine bladder matrix); The ECM fluid matrix was compared to the Integra Fluid Wound (TEM MICROMATRIX®) and Matrix (INTEGRA(TM) Flowable Wound Matrix) (collagen and glycosaminoglycans) glycan). Test article Amount used per site ECM particles 5.0-5.4mg ECM fluid substrate 50μL ECM sheet 1 x 3 x 10 mm piece MatriStem® particles 5.0-5.4mg Integra Fluidity 50μL MatriStem Sheet 1 x 3 x 10 mm piece
[0213] Preparation of flowable substrates: ECM Flowable and INTEGRA™ Flowable 2 mL or more of injectable water should be placed in a 3 mL vial access syringe. The solution was then prepared by aspirating with 100 mL of water (nge) to eliminate air bubbles and adjusting the volume to 2 mL. The cannula was then removed from the vial access syringe. The syringes were connected tip-to-tip to an ECM syringe containing 2 mL of water. The vial access syringe is slowly injected into the vial access syringe to distribute the powder evenly. Mix carefully with 10 to 15 back and forth movements until thoroughly hydrated. The entire paste was pushed into one of the syringes. The empty syringe was discarded and one The 1 mL empty syringe is connected to the remaining ECM paste syringe and 1 mL of ECM paste is added. Alternatively, the INTEGRA® fluid paste was transferred into a 1 mL syringe. The above steps were repeated with a second 1 mL syringe. The paste was then dispensed into a 1 mL syringe for each dose. The INTEGRA™ fluid was remixed before being loaded into a 1 mL syringe for The test and control substances were mixed with 3.0 mL of saline for injection. The solution was applied directly using 1 mL of the solution.
[0214] Implantation: Each animal was implanted with a hamstring through the paravertebral fascia on both sides of the midline of the back. A 2-4 cm skin incision was made extending from the graft site to the spinal cord. At each implantation site, a 5 mm incision was made extending from the graft site to the spinal cord. For implantation, the hemostat is used to cut the muscle approximately 2 cm from the midline and along the muscle fibers. Small pockets parallel to the axis are created, with at least 2.5 cm spacing between implantation sites. Four test articles or four control articles were placed on one side of the paravertebral muscles. The test substances were implanted on the right side and the control substances on the left side in groups. All implantation sites are then closed with non-absorbable sutures and the skin incisions are closed with sutures and / or The wound was closed with skin staples. 50 μL of the fluid preparation, 5 mg of The particle preparation and one piece (1 × 3 × 10 mm) of the sheet preparation were placed in the created muscle pocket. The control material was 50 μL of a bovine-derived wound matrix product (INTEGRA® Flowab le), 5 mg of a particulate preparation of extracellular matrix from porcine urinary bladder (MATRISTEM MICROMATRIX (registered trademark) (registered trademark), and a sheet (1 × 3 × 10 mm) preparation of extracellular matrix from porcine urinary bladder (MA The animals were sacrificed 1, 2 or 4 weeks after implantation. and histological examination was performed.
[0215] Results: The ECM sheet showed significantly less tissue reactivity than the porcine bladder matrix. At 1 week post-implantation, tissue adjacent to the bladder matrix (UBM) showed clear signs of granulation and inflammatory reaction. In contrast, the ECM sheets were scattered with only slight infiltration of granulocytes (Fig. 1A). At the second and fourth weeks, granulation was more pronounced near the UBM sheet. In contrast to the ECM sheets (Fig. 1C and 1E), the tissue adjacent to the ECM sheets was essentially free of granulation. The ECM sheet appeared normal (Fig. 1D and Fig. 1F). It seemed unlikely.
[0216] ECM particles and flowable matrices produced less tissue reactivity than control particles and flowable matrices. For example, in the first week after implantation, the ECM particles showed some inflammation-indicating granulation (Fig. 2B), but to a significantly smaller extent than that of the UBM particles (Fig. 2A). At weeks 2 and 4, the ECM particles showed a significant decrease in granulation (Figures 2D and 2F). In comparison, UBM particles showed substantial inflammation at weeks 2 and 4 (Fig. 2C and Similarly, a bovine-derived wound matrix product (INTEGRA™ Flowable) was found to be granular at week 1. The tumor showed cytosis (Fig. 3A), followed by scarring at the second and fourth weeks (Fig. 3C and bright spots in Fig. 3E). On the other hand, the ECM fluid matrix showed a substantial inflammatory response only during the first week (Figure 3B ), followed by almost complete recovery at weeks 2 and 4 (FIGS. 3D and 3F).
[0217] 6.7. Example 7: Method of Producing Placental ECM from Placental Chorion This example illustrates the preparation of placental ECM from placental chorion, which is first prepared as a paste. A method is disclosed.
[0218] Method 1: Obtain previously isolated and frozen human placenta and thaw at room temperature for ~24 hours. After the placenta is thawed, the chorion is obtained from the placenta. The placenta is then , and cut into 2 x 2 cm strips for processing.
[0219] The placental chorionic tissue was then placed in a container containing 1.5 liters of 1M NaCl solution. The mixture was homogenized using an Omnimixer homogenizer manufactured by Omni International. The homogenized placental chorionic tissue is then placed into a process bag, which is then The volume is filled to 9.2 liters with 1M NaCl solution. The chorionic tissue is washed three times with 1M NaCl solution as follows: (i) the process bag is (ii) the placental chorionic tissue is placed in a process bag and agitated for 10 minutes on an orbital shaker. (iii) 6.2 L of the supernatant was removed by gravity drainage from the process. This step removes blood and debris from the mixture. be.
[0220] After the third washing step, the washed placental chorionic tissue was incubated at room temperature for ~18-26 hours. Mix in 1M NaCl solution (total 3 liters of mixture) on an orbital shaker. The placental tissue is then washed four times with sterile water, similar to the NaCl wash described above. After rinsing with water, the placental chorionic tissue was incubated for ~18-26 h on an orbital shaker at room temperature. - Mix in water (3 liters of mixture total) for ~18-26 hours in water After mixing, the placental chorionic tissue is washed one final time with water in the same manner as described above, and then Then, 6.2 L of 3% sodium deoxycholate was added to the mixture. The final concentration of sodium deoxycholate is 2%.
[0221] The placental chorionic tissue was incubated in 2% deoxyribonucleic acid on an orbital shaker at room temperature for ~72 hours. The placental chorionic tissue was mixed in sodium citrate solution for ~72 hours. After that, it is washed five times with sterile water in the manner described above. Finally, water is added, followed by 1M NaO By adding H dropwise, the pH of the solution is adjusted to about 10-12, making it a basic solution. The membranes are mixed in the basic solution for .about.30 minutes at room temperature on an orbital shaker. After mixing for 30 minutes, the pH of the solution was adjusted to approximately 7.0- Adjusted to 7.5.
[0222] The supernatant is removed from the process bag and the remaining placental chorionic tissue is collected and centrifuged. After centrifugation, the supernatant is removed and the collected placental chorionic tissue is subjected to a final washing step. The pellet is resuspended in sterile water and centrifuged again, after which the supernatant is discarded. The composition is a placental ECM composition containing collagen and elastin, and is a white paste. It would be the form.
[0223] Method 2: Once processing has commenced, the frozen human placenta is thawed at 2-8°C and kept in a biosafety kit. The placenta is removed from the storage container and transferred to a sterile, pre-assembled BSC. It is placed on a discard tray. The placenta is cleaned to remove excess blood and blood clots. The chorion of the placenta is obtained and minced into small pieces. The minced placental material is suspended in sterile water. The mixture is then homogenized using a mechanical homogenizer, which is used to increase the surface area. Generates microscopic tissue particles with a large area and more effectively removes cells and cell debris from placental ECM Homogenized placental chorion tissue was diluted in sterile 1M salt solution to allow for the separation and removal of lysates. The tissue is then transferred to a sterile process bag containing a sodium chloride solution. The solution was diluted with 1 M sodium chloride (NaCl) and stirred on an orbital shaker several times. The placental tissue is then allowed to settle and then drained and washed with additional sterile 1M NaCl solution. The NaCl solution is replaced by replenishing the placental tissue with sterile 1M NaCl. The mixture was stirred in aCl solution for 18-24 hours, then washed with sterile water. is repeated. All processing steps are carried out at room temperature. Exposing placental chorionic tissue to high concentrations of sodium chloride and then to water may have adverse effects on the tissue. This constitutes an "osmotic shock" of blood, blood components, cells and cells of tissues. This helps to clear the placenta of debris. The tissue is then washed with detergent in the next step. They are subjected to a second "osmotic shock."
[0224] The rinsed placental chorionic tissue was then soaked in sterile 0.1-0.3% sodium deoxycholate. Together with 4-8 mM ethylenediaminetetraacetic acid (EDTA) solution, The mixture is then stirred in an ion-processing bag at room temperature for 48-72 hours. After rinsing with sterile water, the tissue was then incubated for a second 18-24 hour period with DOC / EDTA. The tissue is then rinsed with water to remove DOC and EDTA. , sterile water is used.
[0225] Once the water wash is complete, the supernatant is removed from the bioprocess bag and diluted with 2 mM salt. Magnesium chloride solution and 10 U / mL BENZONASE® at pH 8-9 The mixture is replaced and mixed at room temperature for 18-24 hours. It is an endonuclease that degrades all types of nucleic acids (RNA and DNA); The unwanted polynucleotide fragments are washed away by a series of rinses of the placental tissue.
[0226] After rinsing of the placental chorionic tissue to remove residual nucleic acids, the material is subjected to viral inactivation. The fermentation steps are performed at low and high pH. The chorionic tissue was incubated in the presence of sterile 0.67M NaCl solution at pH 3.3 or The mixture is mixed with water and agitated on an orbital shaker at 22±1°C for 24 hours. In the experiment, the pH of the solution was adjusted to ≥ 13 using sodium hydroxide (NaOH). The mixture was mixed in the bioprocess bag on an orbital shaker at 22 ± 1 °C for a minimum of 4 hours. At the end of the NaOH exposure, the pH of the solution is 5.5-9. It will be adjusted to the .0 range.
[0227] After the acid and base treatments were completed, the tissue was incubated with 1M NaCl. The placenta was then mixed on an orbital shaker for 48-72 hours. The hair follicle ECM is washed with sterile water for 18-24 hours to remove debris and residual contaminants. The suspension is centrifuged to produce an ECM paste. The sample may be stored in a -20°C freezer until the product is prepared and sterilized.
[0228] Preparation as sheets: To generate ECM sheets, ECM paste is incubated at 2 °C for 2 h. Thaw at 2°C for 24-48 hours and store in sterile phosphate buffered saline in a biological safety cabinet. The tissue is homogenized to prepare a homogenous ECM suspension and the suspension is resuspended in a buffer. The suspension is dispensed into sterile plastic molds and frozen. Frozen ECM moulds The ECM wafer is dehydrated using freeze-drying. The resulting dehydrated ECM wafer is rehydrated with sterile water. The sheets are then condensed in a vacuum assisted dryer at room temperature for 18-36 hours. The containers are then packed in a plastic bag, sealed with a medical grade sealer, labeled, and then gamma irradiated. It is then sterilized.
[0229] Preparation as particles: To generate ECM particles, the ECM paste is resuspended in sterile water. The mixture was then transferred to a mold and shipped to Thermo Scientific, Marietta, Ontario. H) were frozen using a Controlled Rate Freezer and then The mixture was lyophilized for 48 hours using a LabConco (Kansas City, MO) freeze dryer. Freeze-dried ECM was obtained from Fluid Energy (Telford, PA). The ECM particles are then crushed using a jet mill. It can be filled into amber glass vials and sealed.
[0230] Preparation as a flowable matrix: ECM flowable matrices can be prepared using ECM particles. Typically, ECM flowable matrices are prepared by lyophilizing and pulverizing ECM (ECM particles) in a sterile, It may be prepared by suspending in water or saline.
[0231] The collagen, elastin, fibronectin, and / or laminin content of the ECM , can be analyzed in the manner disclosed in Examples 2, 3, 4 and 5, respectively. The biocompatibility of the CM can be evaluated as disclosed in Example 6.
[0232] 6.8. Example 8: Method for Producing Placental ECM from Placental Chorion (2) This example illustrates the preparation of a placental ECM composition, which is initially prepared as a paste, from placental chorion. This invention discloses a method for manufacturing the same.
[0233] Human placenta obtained from a mother immediately after full-term delivery or previously separated and frozen human placenta The placenta is washed in 0.5M NaCl and then thawed. The amnion, umbilical cord and decidua parietalis are removed from the placenta and the chorionic plate is retained and scrubbed clean. The scrubbed chorion was rinsed in 0.5M NaCl and in water. (rinsed), rinsed overnight in 2% deoxycholic acid, followed by several water rinses The processed chorion is then pulverized and freeze-dried. The resulting composition is a decellularized The resulting ECM paste is suitable for further preparation, such as by grinding.
[0234] Preparation as sheets: To generate ECM sheets, ECM paste is incubated at 2 °C for 2 h. Thaw at 2°C for 24-48 hours and store in sterile phosphate buffered saline in a biological safety cabinet. The tissue is homogenized to prepare a homogenous ECM suspension and the suspension is resuspended in a buffer. The suspension is dispensed into sterile plastic molds and frozen. Frozen ECM moulds The ECM wafer is dehydrated using freeze-drying. The resulting dehydrated ECM wafer is then rehydrated with sterile water. The sheets are then condensed in a vacuum assisted dryer at room temperature for 18-36 hours. The containers are then packed in a plastic bag, sealed with a medical grade sealer, labeled, and then gamma irradiated. It is then sterilized.
[0235] Preparation as particles: To generate ECM particles, the ECM paste is resuspended in sterile water. The samples were then transferred to molds and stored in a Thermo Scientific (Marietta, OH) control laboratory. The samples were frozen in a 300° freezer and freeze-dried using a Labconco (Kansas City, MO) freeze dryer. The freeze-dried ECM was purchased from Fluid Energy (Telfor d, PA) is pulverized using a jet mill to generate ECM particles. The powder can be filled and sealed in amber glass vials.
[0236] Preparation as a flowable matrix: ECM flowable matrices can be prepared using ECM particles. Typically, ECM flowable matrices are prepared by lyophilizing and pulverizing ECM (ECM particles) in a sterile, It may be prepared by suspending in water or saline.
[0237] The collagen, elastin, fibronectin, and / or laminin content of the ECM , can be analyzed in the manner disclosed in Examples 2, 3, 4 and 5, respectively. The biocompatibility of the CM can be evaluated as disclosed in Example 6.
[0238] 6.9. Example 9: Method for Producing Placental ECM from Placental Chorion (3) This example discloses a method for producing a placental ECM composition from placental chorion.
[0239] Human placenta obtained from a mother immediately after full-term birth is used. The amnion, umbilical cord, and decidua parietalis are The placenta is removed and the chorionic plate is retained and scrubbed clean. The chorion was rinsed in 0.1M NaCl and water, and then diluted with 0.067% deoxycholate. They are rinsed overnight in a solution containing acid and 4 mM EDTA, followed by several water rinses. The chorion was then soaked in a solution containing 0.39% deoxycholic acid and 8 mM EDTA. The whole chorion is then rinsed overnight, followed by several water rinses. The processed whole chorion is then freeze-dried. do.
[0240] Preparation as sheets: To generate ECM sheets, ECM is incubated at 2°C to 22°C for 2 Thaw for 4-48 hours and place in sterile phosphate buffer in a biological safety cabinet. The tissue is homogenized to form a homogenous ECM suspension. The ECM is prepared and the suspension is dispensed into sterile plastic molds and frozen. The frozen mold is then dehydrated using freeze-drying. The resulting dehydrated ECM wafer The mixture is rehydrated with sterile water and then condensed in a vacuum assisted dryer at room temperature for 18-36 hours. Sheets are double-pouched, sealed with a medical-grade sealer, and labeled. The container is then sterilized using gamma radiation.
[0241] Preparation as particles: To generate ECM particles, ECM is resuspended in sterile water. The CM paste is formed and transferred to a mold by Thermo Scientific (Marietta, OH). The samples were frozen in a controlled rate freezer at Labconco (Kansas City, MO). The ECM was then freeze-dried for 48 hours using a freeze dryer. The ECM particles are generated by milling using a Nagy (Telford, PA) jet mill. The ground ECM powder can be filled and sealed into amber glass vials.
[0242] Preparation as a flowable matrix: ECM flowable matrices can be prepared using ECM particles. Typically, ECM flowable matrices are prepared by lyophilizing and pulverizing ECM (ECM particles) in a sterile, It may be prepared by suspending in water or saline.
[0243] The collagen, elastin, fibronectin, and / or laminin content of the ECM , can be analyzed in the manner disclosed in Examples 2, 3, 4 and 5, respectively. The biocompatibility of the CM can be evaluated as disclosed in Example 6.
[0244] Characterization of the pre-sterilized ECM compositions prepared in this manner is shown in Table 4. The properties are given on a dry weight basis, as summarized in:
[0245] [Table 4]
[0246] All publications and patent applications cited herein are hereby expressly incorporated by reference. to the same extent as if specifically and individually indicated as encompassed by the For purposes of clarity of understanding, certain details of the invention have been set forth herein. and examples, various modifications may be made without departing from the spirit or scope of the present invention. Modifications may be made, as will be apparent to one of ordinary skill in the art in light of the disclosure herein. There will be.
Claims
1. Characterized by containing approximately 35-55% collagen and approximately 10-30% elastin Extracellular matrix (ECM) composition.
2. 2. The composition of claim 1, comprising less than 0.1% fibronectin.
3. 3. The composition of claim 1 or 2, comprising an undetectable amount of laminin.
4. 4. The method according to claim 1, further comprising administering to said patient a glycosaminoglycan in an amount that is not detectable.
3. The composition according to claim 1.
5. Less than 0.1% fibronectin, undetectable amounts of laminin, and undetectable amounts of glycoproteins. The composition of claim 1, further comprising a cosaminoglycan.
6. Characterized by containing approximately 40-70% collagen and approximately 15-25% elastin ECM composition.
7. 7. The composition of claim 6, comprising less than about 0.1% fibronectin.
8. 8. The composition of claim 6 or 7, comprising less than about 0.1% laminin.
9. 9. The method of claim 6, wherein the composition contains less than about 0.1% glycosaminoglycans. The composition according to any one of claims 1 to 5.
10. Characterized by containing undetectable amounts of cytokines, growth factors, or deoxycholic acid. The composition according to any one of claims 6 to 9.
11. Less than about 0.1% fibronectin, less than about 0.1% laminin, and less than about 0.1% glycosaminoglycans and undetectable amounts of cytokines, growth factors, or deoxycholic acid. and carboxylic acid.
12. Less than about 0.1% fibronectin, less than about 0.1% laminin, and less than about 0.1% glycosaminoglycans and undetectable amounts of cytokines, growth factors, and deoxycholic acid. and carboxylic acid.
13. 13. The method according to claim 1, wherein the ECM is a placental ECM. The composition described above.
14. 14. The composition of claim 13, wherein the placental ECM is human placental ECM. 。
15. 14. The composition according to claim 1, wherein the composition is prepared as a sheet. The composition according to item 3.
16. 16. The sheet according to claim 15, wherein the sheet has a thickness of about 1.5 to 2.5 mm. Composition of.
17. 17. The composition according to claim 1, wherein the composition is formulated as particles. The composition described in
18. 17. The method according to claim 1, wherein the composition is formulated as a flowable matrix.
3. The composition according to claim 1.
19. The ECM composition contains about 35-55% collagen and about 10-30% elastin. (i) removing the amnion, chorion, and umbilical cord from the placenta; (ii) removing any remaining (iii) placing the placental tissue in a solution containing 1M NaCl; and (ii) homogenizing the placental tissue. (iv) contacting the placental tissue with a solution comprising 2% sodium deoxycholate. (v) washing the placental tissue with water; and (vi) soaking in 1 M sodium hydroxide. (vii) contacting the placental tissue with a solution containing a glycerol; and (viii) collecting placental tissue. An ECM composition produced.
20. 20. The composition of claim 19, comprising less than 0.1% fibronectin.
21. 21. The composition of claim 19 or 20, comprising an undetectable amount of laminin.
22. 22. Any of claims 19 to 21, characterized in that it contains undetectable amounts of glycosaminoglycans. The composition according to any one of claims 1 to 5.
23. Less than 0.1% fibronectin, undetectable amounts of laminin, and undetectable amounts of glycoproteins. The composition of claim 22, comprising a cosaminoglycan.
24. The ECM composition contains about 40-70% collagen and about 15-25% elastin. (i) obtaining the chorion from the placenta; (ii) scrubbing the chorion to remove it. (iii) placing the chorionic tissue in a solution containing 0.5 M NaCl; iv) Contacting the chorion with a solution containing 2% deoxycholic acid or sodium deoxycholate (v) rinsing the chorion with water; and (vi) grinding and freeze-drying. and b. a step of extracting an ECM composition from the ECM.
25. 25. The composition of claim 24, comprising less than about 0.1% fibronectin. 。
26. 26. The composition of claim 24 or 25, comprising less than about 0.1% laminin. 。
27. 27. The method of claim 24, comprising less than about 0.1% glycosaminoglycans. The composition according to any one of claims 1 to 5.
28. Characterized by containing undetectable amounts of cytokines, growth factors, or deoxycholic acid.
28. The composition according to any one of claims 24 to 27.
29. Less than about 0.1% fibronectin, less than about 0.1% laminin, and less than about 0.1% glycosaminoglycans and undetectable amounts of cytokines, growth factors, or deoxycholic acid. and carboxylic acid.
30. Less than about 0.1% fibronectin, less than about 0.1% laminin, and less than about 0.1% glycosaminoglycans and undetectable amounts of cytokines, growth factors, and deoxycholic acid. and carboxylic acid.
31. The ECM composition contains about 40-70% collagen and about 15-25% elastin. (i) obtaining the chorion from the placenta; (ii) scrubbing the chorion to remove it. (iii) placing the chorion in a solution containing 1.0 M NaCl; and (iv) 0.05%-0.1% deoxycholic acid or sodium deoxycholate and 3 mM- The chorion is exposed to a first detergent solution containing 5 mM EDTA, and then rinsed with water. (iv) 0.05%-0.1% deoxycholic acid or sodium deoxycholate; contacting the chorion with a second detergent solution containing sodium chloride, followed by rinsing with water; v) freeze-drying.
32. 32. The composition of claim 31, comprising less than about 0.1% fibronectin. 。
33. 33. The composition of claim 31 or 32, comprising less than about 0.1% laminin. 。
34. 34. The method of claim 31, comprising less than about 0.1% glycosaminoglycans. The composition according to any one of claims 1 to 5.
35. Characterized by containing undetectable amounts of cytokines, growth factors, or deoxycholic acid.
35. The composition according to any one of claims 31 to 34.
36. Less than about 0.1% fibronectin, less than about 0.1% laminin, and less than about 0.1% glycosaminoglycans and undetectable amounts of cytokines, growth factors, or deoxycholic acid. and carboxylic acid.
37. Less than about 0.1% fibronectin, less than about 0.1% laminin, and less than about 0.1% glycosaminoglycans and undetectable amounts of cytokines, growth factors, and deoxycholic acid. and carboxylic acid.
38. 38. The method according to claim 19, wherein the ECM is placental ECM. The composition described.
39. 39. The composition of claim 38, wherein the placental ECM is human placental ECM. 。
40. 40. Any of claims 19 to 39, wherein the composition is formulated as a sheet.
2. The composition described in item 1.
41. 41. The method of claim 40, wherein the sheet has a thickness of about 1.5 to 2.5 mm. Composition of.
42. 40. Any one of claims 19 to 39, wherein the composition is formulated as particles. The composition according to item 3.
43. 40. The method according to claim 19, wherein the composition is formulated as a flowable matrix. The composition according to any one of claims 1 to 5.
44. 1. A method of treatment in a subject in need of extracellular matrix (ECM), comprising administering to the subject or contacting a subject with a composition according to any one of claims 1 to 43.
23. A method comprising the steps of:
45. 45. The method of claim 44, wherein the subject has an oral lesion.
46. 45. The method of claim 44, wherein the subject has urinary incontinence.
47. 45. The method of claim 44, wherein the subject has vesicoureteral reflux.
48. 45. The method of claim 44, wherein the subject has gastroesophageal reflux disease.
49. The subject has a disease, disorder, or abnormal condition affecting one or both vocal cords and / or larynx.
45. The method of claim 44, comprising:
50. 45. The method of claim 44, wherein the subject has a glottal insufficiency.
51. 45. The method of claim 44, wherein the ECM is used as a nerve guide. 。
52. 45. The method of claim 44, wherein the ECM is used as a tendon wrap.
53. 45. The method of claim 44, wherein the ECM is used as a substitute for dura mater. 。
54. 45. The method of claim 44, wherein the subject has a cosmetic defect.
55. The cosmetic defects include wrinkles, depressions, creases, stretch marks, scars, sunken eyes, or the like.
55. The method of claim 54, wherein the visible blood vessels that result in dark circles around the eyes are
